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NOVEL ROLES OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-1 
IN LIVER 
 
 Sterol Regulatory Element Binding Protein-1 (SREBP-1) is a conserved 
transcription factor of the basic helix-loop-helix leucine zipper family (bHLH-Zip) 
that primarily regulates glycolytic and lipogenic enzymes such as L-pyruvate 
kinase, acetyl-CoA carboxylase, fatty acid synthase, stearoyl-CoA desaturase 1, 
and mitochondrial glycerol-3-phosphate acyltransferase 1. SREBP-1c activity is 
higher in the liver of human obese patients, as well as ob/ob and db/db mouse 
models of obesity and type 2 diabetes, underscoring the role of this transcription 
factor as a contributor to hepatic steatosis and insulin resistance. Nonetheless, 
SREBP-1 deficient ob/ob mice, do not display improved glycemia despite a 
significant decrease in hepatic lipid accumulation, suggesting that SREBP-1    
might play a role at regulating carbohydrate metabolism. By silencing SREBP-1   
in the liver of normal and type 2 diabetes db/db mice, we showed that indeed, 
SREBP-1 is needed for appropriate regulation of glycogen synthesis and 
gluconeogenesis enzyme gene expression. Depleting SREBP-1 activity more  
than 90%, resulted in a significant loss of glycogen deposition and increased 
expression of Pck1 and G6pc. Hence, the benefits of reducing de novo   
lipogenesis in db/db mice were offset by the negative impact on gluconeogenesis  
and    glycogen  synthesis.  Some   studies  had  also  indicated   that   SREBP-1 
viii 
regulates the insulin signaling pathway, through regulation of IRS2 and a subunit 
of the PI3K complex, p55g. To gain insight on the consequences of silencing 
SREBP-1 on insulin sensitivity, we analyzed the insulin signaling and mTOR 
pathways, as both are interconnected through feedback mechanisms. These 
studies suggest that SREBP-1 regulates S6K1, a downstream effector of 
mTORC1, and a key molecule to activate the synthesis of protein. Furthermore, 
these analyses revealed that depletion of SREBP-1 leads to reduced insulin 
sensitivity. Overall, our data indicates that SREBP-1 regulates pathways     
important for the fed state, including lipogenesis, glycogen and protein synthesis, 
while inhibiting gluconeogenesis. Therefore, SREBP-1 coordinates multiple 
aspects of the anabolic response in response to nutrient abundance. These  
results are in agreement with emerging studies showing that SREBP-1 regulates 
a complex network of genes to coordinate metabolic responses needed for cell 
survival and growth, including fatty acid metabolism; phagocytosis and    
membrane biosynthesis; insulin signaling; and cell proliferation.  
 
Núria Morral, Ph.D., Chair 
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INTRODUCTION 
 
1. Control of carbohydrate and lipid metabolism by insulin  
Maintaining glucose homeostasis under fed and fasting conditions is a 
vital physiological response. This balance is mainly orchestrated by the action of 
the hormones insulin and glucagon, which have opposite functions. Insulin is an 
anabolic hormone involved in promoting glucose uptake, glycogen synthesis, 
glucose conversion to lipid, and inhibition of glucose production. Under fed 
conditions, when plasma glucose levels are elevated, insulin is released from β-
cells in the pancreas, facilitating glucose uptake by tissues, and clearing glucose 
from the circulation. In contrast, during fasting or after exercise, insulin secretion 
is diminished while glucagon is released from α-cells in the pancreas. Glucagon 
promotes glycogen breakdown and de novo glucose production, resulting in 
increased plasma glucose levels [1].  
Insulin exerts its action in four main target tissues: skeletal and cardiac 
muscle, adipose tissue, and liver (Fig. 1). Insulin induces glucose uptake in the 
muscle by promoting the translocation of the GLUT4 glucose transporter to the 
cell membrane [2]. Insulin-mediated GLUT4 relocation enables glucose uptake 
by this tissue and is a main mechanism to reduce glucose levels from the 
circulation. During basal and hyperinsulinemic conditions, glucose uptake by the 
skeletal muscle accounts for 20 and 75% of insulin-dependent glucose disposal, 
respectively [3]. Under the fed state, glucose is oxidized into pyruvate through 
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glycolysis, which enters mitochondria and the Krebs cycle to produce ATP. In 
addition, glucose can be stored as glycogen [4]. 
Similarly, in the adipose tissue, insulin enhances glucose uptake by 
facilitating GLUT4 translocation to the cell membrane. Glucose is then 
metabolized to generate glycerol-3-phosphate, which provides the backbone for 
fatty acid esterification and triglyceride synthesis. In addition, insulin promotes 
transcription of the enzymes necessary for fatty acid and triglyceride synthesis. 
During fasting conditions, low insulin and high AMP/cAMP activate AMPK and 
PKA, blocking lipogenesis and activating the enzyme hormone sensitive lipase to 
reverse this process and release fatty acids into the circulation [4]. 
The liver is a versatile organ that has the ability to synthesize and 
breakdown glucose and fatty acids in response to nutrient/energy conditions, and 
is a critical tissue to maintain blood glucose levels within the normal range. 
Glucose uptake by the liver is mediated by the GLUT2 transporter and is not 
contingent on insulin [5]. However, in the transition from the fasted to the re-fed 
state, insulin stimulates gene expression and activity of the enzymes involved in 
the glycolysis, glycogen synthesis, and lipogenesis pathways. Glucose disposal 
to generate glycogen in the liver, represents ~17% of postprandial glucose [6]. 
Under fed conditions, glucose entering the hepatocyte is oxidized to generate 
ATP. When the levels are high, citrate and ATP inhibit phosphofructokinase-1, 
redirecting metabolites to the glycogen synthesis pathway as well as the pentose 
phosphate pathway and subsequently to palmitate synthesis [de novo 
lipogenesis (DNL) pathway] [4]. The newly synthesized palmitate molecule can 
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be desaturated and/or elongated, and used to produce triglycerides, 
phospholipids, ceramides, or other lipids. In addition, the liver receives fatty acids 
from the diet and from the circulation, which are released from triglyceride 
breakdown in the adipose tissue. Triglycerides generated in the liver remain in 
the cytoplasm as droplets, or are secreted into the circulation through very low-
density lipoprotein (VLDL) for use by other tissues.  
Insulin inhibits glycogen breakdown (glycogenolysis) and 
gluconeogenesis, preventing the production and release of glucose to the blood 
stream during fed conditions, when plasma glucose levels are high. However, 
under fasting conditions, glucose is produced from amino acids, glycerol, and 
lactate through the gluconeogenesis pathway and from glycogen breakdown. 
During fasting, hepatic glucose output is important for maintaining euglycemia. In 
addition, the liver receives a large supply of fatty acids from the adipose tissue, 
which are then oxidized to generate ketone bodies. These are secreted into the 
circulation and provide an alternative energy source for other organs, such as the 
brain and the skeletal muscle [4]. 
The liver also plays an important role at maintaining cholesterol 
homeostasis, and in the synthesis of bile salts. Furthermore, the liver synthesizes 
non-essential amino acids and makes most of the plasma proteins such as 
albumin and clotting factors. The liver also breaks down amino acids by 
deamination and transamination, and removes ammonia from the bloodstream, 
converting it into urea for excretion [4]. 
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Figure 1. Insulin action in the principal target tissues. Insulin secreted from 
the pancreas, inhibits fatty acid release from the adipose tissue, decreases 
glucose output in the liver, and increases glucose uptake by the skeletal muscle. 
However, various contributing factors, such as insulin resistance/diabetes and 
hyperinsulinemia, lead to decreased insulin action in target tissues. As a result, 
hepatic glucose production increases and glucose disposal in the skeletal muscle 
is reduced, leading to increased blood glucose levels. In addition, lipolysis in 
adipose tissue is increased, raising the levels of circulating fatty acids. Both the 
increase in fatty acids and blood glucose exacerbate type 2 diabetes. Source: 
Image from [7].  
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2. Insulin resistance and type 2 diabetes 
Insulin resistance is defined as decreased sensitivity or responsiveness to 
the action of insulin to exert its control on metabolism, resulting in multiple 
metabolic derangements in insulin-sensitive tissues [8]. Muscle, pancreatic β-
cells, liver, and adipose tissue are contributors to the development of this 
pathology [9]. The causes of insulin resistance and hyperglycemia are complex 
and controversial. It is likely that insulin resistance starts simultaneously in more 
than one tissue. Nevertheless, multiple studies have provided evidence that 
adipose tissue dysfunction plays a critical role in the development of insulin 
resistance in other tissues. Insulin resistance in adipocytes leads to increased 
circulating free fatty acids (FFAs) due to up-regulation of lipolysis [10]. Excess 
circulating levels of FFAs causes lipid accumulation in liver, muscle, and β-cells, 
where it interferes with insulin signaling/action and causes lipotoxicity [11, 12]. 
Diacylglycerol and ceramide have been linked to insulin resistance by activating 
several isoforms of PKC [13] and protein phosphatase 2A, although the role of 
ceramides in the liver has been disputed [14]. PKC activation hinders IRS activity 
and downstream insulin signaling by phosphorylating IRSs at serine residues [15, 
16]. In addition, free fatty acids activate c-Jun N-terminal kinase (JNK) [14, 17, 
18], which interferes with IRS signaling. In the liver, JNK contributes to the 
development of insulin resistance and non-alcoholic steatohepatitis (NASH) [19, 
20]. 
Insulin resistance leads to decreased glucose disposal in skeletal muscle 
as well as dysregulation of glucose transport and metabolism in adipose tissue, 
6 
and lack of inhibition of hepatic glucose production in the liver [8, 12]. The main 
consequence of lack of proper glucose metabolism in skeletal muscle and liver is 
high blood glucose levels, stimulating the pancreas to secrete insulin (Fig. 1). 
Hyperinsulinemia further exacerbates insulin resistance in target tissues.  
The metabolic syndrome is a cluster of conditions that increase the risk of 
heart disease, stroke and diabetes. These conditions include: abdominal (central) 
obesity; elevated blood pressure and serum triglycerides; insulin resistance 
(elevated fasting glucose); and low high-density lipoprotein (HDL). Metabolic 
syndrome is becoming more common in the USA, due to the increase in obesity 
rates (more than 64% of the adult population is overweight). Without a change in 
lifestyle, metabolic syndrome may develop into type 2 diabetes (T2DM).  
Non-insulin-dependent or type 2 diabetes mellitus is characterized by an 
elevated blood glucose concentration that derives from inadequate insulin action 
in target tissues and from abnormal insulin secretion [1]. The criteria for 
diagnosis of diabetes are: fasting plasma glucose ≥126 mg/dL (7.0 mmol/L); or 2-
hour plasma glucose ≥200 mg/dL (11.1 mmol/L) during an oral glucose tolerance 
test (with 75 g glucose dissolved in water); or HbA1c ≥6.5% (48 mmol/mol); or 
random plasma glucose ≥200 mg/dL (in a patient with classic symptoms of 
hyperglycemia) [21]. The criteria for diagnosis of pre-diabetes are defined as: 
fasting plasma glucose of 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L); or 
2-hour plasma glucose of 140 mg/dl (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L) 
during an oral glucose tolerance test; or HbA1c 5.7-6.4% (39-46 mmol/mol) [21]. 
7 
Hyperinsulinemia is seen in the first stages of the disease due to β-cell 
compensation for the insulin resistant state. However, at later stages of the 
disease, loss of β-cell mass occurs, and the pancreas can no longer secrete 
enough insulin to compensate for the high plasma glucose levels. At this stage, 
individuals require the use of exogenous insulin to treat hyperglycemia [1]. 
Individuals with type 2 diabetes who do not practice a strict glucose control, 
develop complications at the long-term, including neuropathy, nephropathy, 
retinopathy, cardiovascular disease, stroke, and peripheral vascular disease, 
leading to lack of healing, gangrene, and amputation [22]. 
 The prevalence of T2DM has escalated to alarming proportions, promoted 
by a dramatic increase in the incidence of obesity and a sedentary lifestyle. The 
Centers for Disease Control and Prevention have estimated that 29.1 million 
Americans (or 9.3% of the population) have diabetes [23]. In addition, the direct 
medical costs are currently estimated at $176 billion, and another $69 billion 
have been estimated as a result of disability, work loss, and premature death. 
The average medical expenses among people with diagnosed diabetes are 2.3 
times higher than people without diabetes [23]. Given the economic burden of 
this disease, there is a pressing need to understand the mechanisms leading to 
the metabolic abnormalities characteristic of this condition and develop novel 
therapies. 
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3. Hepatic steatosis and non-alcoholic fatty liver disease (NAFLD) 
 Non-Alcoholic Fatty Liver Disease (NAFLD) is a hallmark of obesity and 
type 2 diabetes mellitus, and is characterized by the accumulation of lipids in the 
liver of individuals who consume little, if any, alcohol [24]. Among individuals with 
T2D, the prevalence of NAFLD is as high as 75%. NAFLD is also high in the 
general USA population, affecting approximately 30% of individuals [25, 26]. The 
NAFLD spectrum (Fig. 2) is comprised of a two hit theory in which the first hit 
alters the hepatic pathway of fatty acid uptake, synthesis, degradation, and 
secretion, making the liver more vulnerable to the second hit, where 
inflammation, oxidative stress, and mitochondrial dysfunction are present, 
leading to non-alcoholic steatohepatitis (NASH) [27]. This pro-inflammatory 
environment activates stellate cells, leading to fibrosis, and if exaggerated, to 
cirrhosis. Patients at this stage of the disease may require a liver transplant. In 
addition, the risk of hepatocellular carcinoma increases [28].  
 
 
 
Figure 2. Non-alcoholic fatty liver disease spectrum. 
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Multiple factors contribute to the development of NAFLD. As mentioned above, in 
individuals with insulin resistance, lipolysis in the adipose tissue is increased due 
to enhanced activity of hormone-sensitive lipase (HSL). Excess circulating free 
fatty acids are taken up by the liver, leading to hepatic lipid accumulation and 
increasing very-low density lipoprotein production [29, 30]. In addition, the influx 
of fatty acids into the liver increases levels of various lipids such as 
diacylglycerols and ceramides, known inhibitors of the insulin signaling pathway 
[31]. Decreased insulin signaling leads to inadequate inhibition of 
gluconeogenesis, increasing hepatic glucose production. However, the de novo 
lipogenesis (DNL) pathway remains active, further exacerbating lipid 
accumulation. This phenomenon is known as selective insulin resistance, and it 
leads to a combination of hyperglycemia and hypertriglyceridemia. Hepatic 
insulin resistance and dyslipidemia contribute to increase the risk of 
cardiovascular disease and stroke [29, 32, 33]. 
An inverse relationship exists between DNL and fatty acid oxidation 
(FAO). In the conversion of glucose to palmitate, malonyl-CoA is produced by the 
enzyme acetyl-CoA carboxylase (ACAC, aka ACC1/2) from the carboxylation of 
acetyl-CoA. Malonyl-CoA is an allosteric inhibitor of the rate limiting enzyme 
carnitine palmitoyltransferase 1 A (CPT-1A). CPT-1A transfers the acyl group of 
acyl-CoA to carnitine, in the mitochondrial membrane. The acyl group is then 
translocated into mitochondria for oxidation [34]. Thus, under fed conditions, 
when DNL increases, malonyl-CoA prevents the oxidation of the newly 
synthesized fatty acids [35]. DNL is significantly increased in the liver of patients 
10 
with non-alcoholic fatty liver disease (NAFLD), and accounts for 26% of 
triglycerides relative to just ~5% in normal individuals [36]. Moreover, DNL is 
elevated in the fasted state and does not increase postprandially [36]. The higher 
rate of DNL in insulin resistant states leads to increased levels of malonyl-CoA 
synthesis and higher inactivation of CPT-1A, contributing further to heighten 
hepatic steatosis.  
  
4. Sterol Regulatory Element Binding Proteins (SREBPs) 
Two major transcription factors regulate expression of the enzymes 
implicated in de novo lipogenesis: Sterol Regulatory Element-Binding Protein-1c 
(SREBP-1c) [37-39], whose expression is activated by insulin; and 
Carbohydrate-Responsive Element-Binding Protein (ChREBP) [40, 41], which 
becomes activated upon increased glucose oxidation and upon feeding a 
carbohydrate-rich diet. These master regulators increase the expression of 
enzymes in the DNL pathway such as acetyl-CoA carboxylase (Acac), fatty acid 
synthase (Fasn), and liver pyruvate kinase (Pklr). Notably, increased levels of 
SREBP-1c activity is linked to hepatic steatosis and insulin resistance in human 
obese patients [42]. Because of its dependence on insulin for transcription and 
for its processing to the active form, SREBP-1c has been the focus of intensive 
research to understand its contribution in hepatic insulin resistance, and it is a 
predicted candidate for therapeutic drug development. 
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4.1. SREBPs gene structure and isoforms 
The SREBPs are transcription factors of the basic helix-loop-helix-leucine 
zipper family (bHLH-Zip) that are conserved from yeast to humans and play 
significant roles in the regulation of cholesterol, fatty acid and triglyceride 
synthesis. SREBPs are encoded by two well-characterized genes, SREBP-1 and 
SREBP-2. SREBP-1 is transcribed into two separate isoforms known as SREBP-
1a and SREBP-1c [43-45]. Both SREBP-1 and -2 genes have been cloned and 
identified in several mammalian species, including human, mouse and rat.  
In humans, the SREBP-1 gene is located in the short arm of chromosome 
17 (17p11.2) and is 26-Kb long, containing 22 exons and 20 introns [46]. Due to 
the presence of an alternative promoter start site in this gene, two splice variants 
are generated yielding SREBP-1a and SREBP-1c (Fig. 3). The SREBP-1 
isoforms differ in their first exon at the 5’ end. In SREBP-1a, 12 negatively 
charged amino acids encoded from exons 1 and 2 are part of a 42 amino acid 
transcription activation domain (see Fig. 3 for structure and function of the 
different protein domains). Upon deletion of this activation domain, human 
SREBP-1a maintains the ability to bind to Sterol Regulatory Element motifs 
(SRE), but is unable to activate transcription. In contrast, the activation domain in 
SREBP-1c is only 24 amino acids long, with 7 negatively charged amino acids 
[47]. Unlike the mouse SREBP-1 mRNA, human SREBP-1a and -1c mRNA can 
undergo alternative splicing at the 3’ ends [45]. In addition, exon 17 encodes the 
last amino acid shared between the two isoforms, with SREBP-1a having 113 
additional amino acids within exons 18a and 19a, and SREBP-1c having 37 
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additional amino acids within exons 18c and 19c in humans [46]. The function 
and importance of the alternative splicing in the SREBP-1 regulatory domain is 
still unclear. 
 The human SREBP-2 gene is located in the long arm of chromosome 22 
(22q13) and is 72-Kb long, containing 19 exons and 18 introns (Fig. 3) [46]. 
Furthermore, gene structure analysis revealed that SREBP-2 introns are larger 
than the corresponding introns in SREBP-1, resulting in SREBP-2 being 2.8 fold 
larger than SREBP-1 [48].   
SREBP-1 and SREBP-2 proteins share roughly 47% of the amino acid 
sequence [43], and have three domains: 1) an NH2- terminal domain of ~480 
amino acids (also known as the transcription factor domain) responsible for DNA 
binding, as well as for homo- or heterodimerization, and for transcription 
activation; 2) a middle hydrophobic region of ~80 amino acids containing two 
hydrophobic transmembrane segments that allows the protein to anchor to the 
ER membrane and nuclear envelope; and 3) a long COOH-terminal domain of 
~590 amino acids involved in posttranslational regulation, also known as the 
regulatory domain (Fig. 3). One structural difference in the SREBP-2 protein is 
the existence of a glutamine-rich region, making up to 27% of the 121 amino 
acids. This glutamine-rich domain interacts with specific co-activators, and may 
explain the functional differences between the SREBP-1 and -2 proteins [44, 49]. 
It should be noted that SREBPs are unique among the bHLH-Zip family proteins, 
due to their ability to bind to SRE motifs, in addition to E-boxes [50]. This dual 
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binding feature is due to the presence of a unique tyrosine in the conserved basic 
domain, in place of an arginine, the amino acid found in most bHLH proteins [50].  
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Figure 3. Graphic representation of genes encoding human SREBP 
isoforms. SREBP-1a and SREBP-1c are transcribed from SREBP-1 through 
alternative promoters and splicing. Each blue box denotes an exon in SREBP-1a 
or SREBP-1c. Red boxes denote the exons specific to the SREBP-1c isoform, 
with two main exons in the C terminus. SREBP-2 encodes one transcript, with 
exons denoted by grey boxes. Below the transcripts and encoding exons are the 
protein domains for SREBP-1a and 1c, and SREBP-2. The three proteins have 
an analogous NH2-terminal domain, which includes the transactivation domain 
and bHLH-ZIP motif for DNA binding and dimerization. In addition, all have a 
transmembrane domain for localization to the endoplasmic reticulum membrane 
and a regulatory domain at the C terminus. Source: adapted from [51].  
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4.2. Transcription of SREBP genes 
As mentioned above, the first exon of the SREBP-1c isoform is of different 
length and composition, suggesting SREBP-1c may be a weaker transcription 
activator than SREBP-1a. Indeed, transgenic mice overexpressing either 
SREBP-1a or SREBP-1c induce a different fold-level of transcription of genes 
involved in the fatty acid synthesis pathway. Fatty acid synthase and acetyl CoA 
carboxylase gene expression is increased 9- and 16-fold, respectively, in 
SREBP-1a animals, and only 2- and 4-fold in SREBP-1c mice [52]. In addition, 
expressing SREBP-1a or -1c in HEK293 cells under the control of the 
phosphoenolpyruvate carboxykinase (PEPCK), thymidine kinase (TK), or 
cytomegalovirus (CMV) promoters, leads to differential levels of target gene 
expression. Promoters inducing low (PEPCK) or moderate (TK) amounts of 
SREBP-1a and -1c demonstrated similar trends of transcription activation to 
those seen in mouse liver, i.e., SREBP-1a being a stronger activator than 
SREBP-1c. Overall, these results confirm that SREBP-1a is a stronger 
transcription factor than SREBP-1c under physiological conditions.  
In addition, expression of SREBP-1 varies among tissues. Of note, the 
liver, white and brown fat, brain, and kidney of mice have higher levels of the 
SREBP-1 transcript than muscle or spleen [45]. Likewise, in humans, SREBP-1 
expression is highest in liver, kidney, and white adipose tissue, while lower in the 
muscle. However, SREBP-1 expression is also lower in brain, differing from the 
mouse. The ratio between the two isoforms, SREBP-1c and -1a, are distinct in 
each tissue as well. Expression of SREBP-1c is highest in the liver of both 
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human and mouse, with a ratio of 1c:1a being 6:1 in humans and 9:1 in the 
mouse [45]. In mouse, SREBP-1c is also higher in white and brown fat, brain, 
and skeletal muscle. In the spleen, testis, intestine, and thymus, the ratio is 
flipped, and SREBP-1a is expressed at higher levels than -1c. In humans, the 
ratio is similar to that in the mouse, and SREBP-1c is more abundant than -1a in 
adrenal gland, ovary, brain, white adipose tissue, and muscle [45]. Although 
SREBP-1c seems to be the predominantly expressed transcript in animal tissues, 
the SREBP-1a isoform is primarily expressed in cell lines, including the HepG2 
human hepatoma cell line, and mouse 3T3-L1 pre-adipocytes, with a 1a:1c ratio 
>2-fold [45]. 
In the liver, SREBP-1a is constitutively expressed, while expression of 
SREBP-1c is inducible and increases in the fed state, in response to insulin. 
Transcription activation of SREBP-1c is the primary determinant of the amount of 
active mature protein in the liver, although insulin also promotes its processing 
from precursor to mature form (described in detail in 4.4). Studies have shown 
that wild type mice fasted for 24 hours had lower SREBP-1c and SREBP-2 
levels, 40% and 30% respectively, in comparison to non-fasted mice. 
Furthermore, re-feeding mice with a high carbohydrate/low fat diet for 12 hours, 
after a 24 hour fast, led to increased levels of SREBP-1 in the liver, with no 
change in SREBP-2 [53]. In addition, studies showed that rats treated with the 
drug streptozotocin (STZ), a known inhibitor of β-cell function in the pancreas, 
had decreased levels of SREBP-1c mRNA, due to insulin deficiency. However, 
treatment with insulin in these animals reversed this result. Moreover, treatment 
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with insulin did not affect SREBP-1a or SREBP-2 mRNA levels suggesting 
selective transcription activation of SREBP-1c by insulin in the liver [54]. 
 Multiple key binding motifs are present in the SREBP-1c promoter, 
including liver X receptor (LXR), specificity protein 1 (Sp1), nuclear factor Y (NF-
Y), and SREBP itself [55]. Insulin-dependent SREBP-1c transcription regulation 
requires LXR, although the mechanism has not been elucidated [37, 56]. LXRs 
bind to the SREBP-1c promoter as heterodimers with retinoid X receptors 
(RXRs), a family of nuclear receptors activated by their endogenous ligand 9-cis 
retinoic acid [57] and rexinoids (synthetic agonists) [58]. LXRs are activated by 
oxysterols (cholesterol derivatives). An important LXR ligand of note is the 24(S)-
25-epoxycholesterol (24.25-EC), abundantly present in the liver [59, 60]. 
Evidence that LXRs are critical regulators of SREBP-1c came from studies in 
LXRα null mice. These animals have decreased levels of SREBP-1c and fatty 
acid synthesis gene expression in the liver [61]. In addition, animals treated with 
the synthetic LXR-selective agonist (T0901317) showed increased levels of 
plasma triglycerides, as well as increased fatty acid synthesis gene expression in 
the liver [62]. Upon studying the mouse SREBP-1 promoter, the binding sites for 
LXR/RXR complex, LXR elements (LXREs), were identified [56]. SREBP-1c 
activation through LXR is attenuated when both LXREα and LXREβ motifs are 
deleted [63]. In vitro studies have demonstrated that SREBP-1c activity is 
suppressed by polyunsaturated fatty acids (PUFAs) due to competition with LXR 
ligands, which prevents binding of the LXR/RXR heterodimer to the LXRE site in 
the SREBP-1c promoter [64, 65]. In addition, studies performed on ob/ob mice 
18 
(an animal model of type 2 diabetes and obesity lacking leptin activity) fed a 
PUFA diet, showed a decrease in SREBP-1c and in triglycerides in the liver, as 
well as improved hepatic steatosis and insulin resistance, further validating the 
regulation of SREBP-1c through PUFAs [66]. 
One additional regulator of SREBP-1c is the transcription factor 
peroxisome proliferator-activated receptor α (PPAR-α). Similar to PUFAs, PPAR-
α competes with LXR for RXR binding on the SREBP-1c promoter. In vitro 
experiments showed that PPAR-α overexpression hindered LXR/RXR-mediated 
SREBP-1c transcription [67]. Similarly, mice under fasting conditions and treated 
with a PPAR agonist resulted in reduced LXR-mediated SREBP-1c activation 
and decreased LXR/RXR heterodimer formation [67]. Remarkably, 
overexpressing LXR or LXR ligands decreases PPAR-α/RXR formation, resulting 
in diminished PPAR-α signaling [68]. It should be noted that PUFAs are well-
known activators and PPAR-α ligands. Since PPAR-α activity is increased during 
fasting and decreased under fed conditions [69], while LXR is active during fed 
conditions, PPARα and LXR may coordinate fatty acid metabolism during fasted 
and fed conditions by mutual inhibition. 
 The transcriptional regulation of SREBP-1a is much simpler than that of 
SREBP-1c. The promoter is small and has a minimal structure, consisting of two 
SP1 binding sites [70], and an early growth response protein 1 (EGR-1) [71]. In 
vitro promoter studies demonstrated that increased EGR-1 dislocates the SP1 
bound transcription factor from the SREBP-1a promoter, suggesting that EGR-1 
might act as an inhibitor for SREBP-1a transcription activity [71]. 
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4.3. Gene targets of SREBPs 
 SREBP-1a and SREBP-1c transcriptionally upregulate genes encoding 
enzymes in the glycolysis and lipogenesis pathways, such as L-pyruvate kinase 
(Pklr), fatty acid synthase (Fasn), acetyl-CoA carboxylase (Acac), ATP-citrate 
lyase (Acly), acetyl-CoA synthetase (Acss), long-chain fatty acyl elongase (Elovl), 
stearoyl-CoA desaturase 1, 2 and 3 (Scd), mitochondrial glycerol-3-phosphate 
acyltransferase 1 (Gpam) (Fig. 4) [72]. In addition, SREBP-1a controls 
expression of some enzymes necessary for de novo synthesis of cholesterol 
such as 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) synthase (Hmgcs), HMG-
CoA reductase (Hmgcr), squalene synthase (Sqs), as was the LDL receptor 
(Ldlr) [72, 73]. In addition, SREBP-1 has been shown to directly bind to the 
promoters of insulin receptor substrate 2 (Irs2), phosphatidylinositol-3 kinase 
regulatory subunit p55ɣ (PIK3R3), heme oxygenase 1 (Hmox1), caspase-2 
(Casp2), glycogen synthase kinase 3 alpha (Gsk3α), and cyclin-dependent 
kinase inhibitor p21 (Cdkn1a) [74-79], which indicates SREBP-1 plays a role at 
coordinating other cellular functions, including insulin signaling and the response 
to stress. SREBP-2, instead, largely regulates genes involved in de novo 
synthesis of cholesterol, including mevalonate kinase (Mvk), acetoacetyl-CoA 
thiolase (Acat), HMG-CoA synthase, HMG-CoA reductase, lanosterol synthase 
(Lss), LDL receptor (Fig. 4) [72].  
 
 
 
20 
 
 
 
 
Figure 4. SREBP-1 and SREBP-2 gene targets. SREBP-1 mostly regulates 
genes of the glycolysis and fatty acid synthesis pathways, while SREBP-2 
controls expression of de novo cholesterol synthesis. 
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4.4. Regulation, proteolysis, and processing of SREBPs 
 SREBPs play a critical role in fatty acid and cholesterol synthesis. 
Consequently, SREBP activity is tightly regulated to maintain lipid homeostasis 
and respond appropriately to nutrient stimuli. In addition to being regulated 
transcriptionally, SREBPs are regulated post-translationally by proteolytic 
processing. SREBP-1a, -1c, and -2 are generated as inactive 125-KDa 
precursors (~1,150 amino acids) bound to the endoplasmic reticulum (ER). 
Under low sterol conditions or high insulin, SREBPs are transported to the Golgi 
apparatus, where they are cleaved, releasing the active 60-KDa NH2-terminal 
fragment (~470 amino acids). Finally, the active transcription activator fragment 
enters the nucleus, binding regulatory elements in gene promoters for 
transcription to ensue [49, 80, 81]  (Fig. 5).  
 Several processing steps take place to cleave the SREBP precursor and 
transport it to the Golgi apparatus, and most of the details of this process has 
been studied for SREBP-2 and SREBP-1a, which regulate cholesterol 
biosynthesis. The SREBP-cleavage activating protein (SCAP) is bound to 
SREBPs and acts as a sterol sensor. The Insulin-Induced Genes (INSIGs) bind 
to the sterol-sensing domain of SCAP in the presence of sterols. There are two 
isoforms of INSIG, denoted as INSIG-1 and INSIG-2. Notably, INSIG-1 
expression is high in human liver. Studies performed in SCAP deficient cell lines, 
showed that expressing SCAP protein increased processing of SREBP-1a and 
SREBP-2, in the absence of sterols [82]. However, under the same conditions, 
the process was inhibited when INSIG-1 was overexpressed. In addition, 
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transgenic mice overexpressing INSIG-1 in their livers have decreased SREBP-
1c and SREBP-2 expression in the nucleus in comparison to control mice [83]. 
Taken together, this would suggest that sterols bind to the SCAP protein causing 
a modification that allows the INSIG-1 protein to bind to SCAP, hindering SREBP 
processing and trapping it in the ER [82]. In the absence of sterols, INSIG-1 frees  
SCAP, which chaperones SREBPs from the ER to the Golgi apparatus (Fig. 5).   
Additional information revealed that the SREBP-SCAP complex, during 
sterol deficiency, assembles in coat-protein complex II (COPII) coated vesicles to 
allow exit from the ER to the Golgi. Specifically, Sec24, which binds to SCAP and 
is one of the COPII proteins required for COPII-coated vesicles, is part of the 
Sec23/Sec24 complex that imparts proper clustering of membrane proteins such 
as SREBP into budding vesicles for transport [84]. When INSIG-1 binds to SCAP 
in the presence of sterols, COPII protein, Sec24 is unable to bind to the 
hexapeptide sorting signal (MELADL) in SCAP, impeding any protein cargo (i.e. 
SREBP), to be transported out of the ER [85]. Thus, the role of INSIG-1 together 
with Sec24 is an important part of the regulation and proteolytic processing of 
SREBPs. 
 Once in the Golgi, SREBPs undergo two consecutive cleavages, 
facilitated by two Golgi-associated proteases, Site-1 (S1-P) and Site-2 (S2-P), 
releasing the NH2-terminal fragment [86]. Proteolytic cleavage of the SREBP 
precursor in sterol-depleted cells generates a water soluble 68-KDa mature 
fragment, which is translocated to the nucleus, where it activates transcription of 
target genes (Fig. 5). 
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Figure 5. SREBP proteolytic processing. Increased sterol (cholesterol and 
lanosterol) levels in the ER membrane promotes the interaction between the 
Scap/SREBP and Insig-1, stabilizing the complex and retaining it in the 
endoplasmic reticulum (ER). HMG-CoA reductase is stimulated to bind to Insig-1, 
which is bound to the gp78/VCP complex for ubiquitination and degradation, 
preventing cholesterol synthesis. Under low sterol conditions, Insig-1 interacts 
with the gp78/VCP complex, undergoing ubiquitination and degradation, 
permitting the Scap/SREBP complex to exit the ER via the Sec23/Sec24/Sar1 
complex. SREBP is further processed in the Golgi apparatus by the S1P and 
S2P proteases, releasing the mature form of SREBP. SREBP is then 
translocated to the nucleus and can then bind to promotors of its target genes. 
Abbreviations: Insig-1, Insulin-induced gene 1; bHLH, SREBP N-terminal 
transcription factor domain; Reg, SREBP C-terminal regulatory domain; Scap, 
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SREBP-cleavage activating protein; gp78/VCP, glycoprotein 78/valosin-
containing protein complex; Ub, Ubiquitin; Sec23/Sec24/Sar1, protein transport 
protein 23/protein transport protein 23/secretion-associated RAS-related protein 
1 complex; S1P, site-1 protease; S2P, site-2 protease. Source: combined image 
from [87]. 
 
 
 
One important downstream target of SREBP-1a and SREBP-2 is the low-
density lipoprotein (LDL) receptor [88]. The LDL receptor binds and internalizes 
plasma LDL. During low cholesterol conditions, the LDL receptor is abundantly 
expressed (in addition to genes involved in de novo synthesis of cholesterol [81]), 
while under high cholesterol conditions, it is inhibited, reducing uptake of LDL. 
Thus the amount of cholesterol in cells is regulated through feedback inhibition of 
the LDL receptor gene, and SREBPs play a key role in that process [89]. 
Unlike SREBP-1a and SREBP-2, sterols do not play an important role in 
the regulation and processing of SREBP-1c. Both, in vivo and in vitro studies, 
have revealed that insulin and fatty acids are the essential players in the 
production of the mature form of SREBP-1c. Studies performed in a primary 
hepatocyte cell line (H2.35) treated with cholesterol revealed a decrease in 
SREBP-2 processing, but minimal effect on SREBP-1c processing from the ER 
[90]. However, when cells were treated with the monosaturated fatty acid oleate, 
SREBP-1c processing was decreased, without affecting SREBP-2 [90]. 
Furthermore, mice fed a PUFA-containing diet, had reduced SREBP-1c mature 
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form, with no effect on the precursor form, suggesting that PUFAs inhibit the 
processing of SREBP-1c [91].  
Insulin is an important and the best characterized regulator of SREBP-1c 
processing, and INSIG-2 plays a significant role in this process. The Insig2a 
transcript is abundantly expressed in the liver, while the Insig2b isoform is 
ubiquitously expressed [92]. Yabe and colleagues uncovered that under fed 
conditions, insulin decreases Insig2a expression in the liver. In contrast, Insig2a 
increases under fasting and decreases again upon refeeding [93]. Notably, 
normal expression levels of INSIG-1 do not affect SREBP-1c processing in the 
liver under fed or refed conditions [83]. Moreover, since Insig2a is decreased 
under fed conditions, this would permit SREBP-1c (which is needed under the 
fed state) to be processed from the ER to the nucleus [93]. Insulin also improves 
the stability of the mature form of SREBP-1c in the nucleus [94]. In addition, 
because Insig2a is repressed by insulin, and INSIG-1 has a minimal effect on 
SREBP-1c processing despite high levels of cholesterol, SREBP-1c is still able to 
be processed to mature form under fed conditions [93].  
 
4.5. Degradation of SREBPs 
 In addition to transcription and processing, regulation of SREBPs also 
takes place through protein degradation. Multiple modifications influence its 
decay, including phosphorylation, ubiquitination and acetylation. GSK3β directly 
phosphorylates SREBP-1a at Thr426 and Ser430, priming the molecule for 
ubiquitination by the ubiquitin ligase Fbw7 [95]. SREBP-1c binding to the DNA of 
26 
target genes enhances the interaction with GSK3β [95]. Furthermore, CDK8 
phosphorylates SREBP-1c, which enhances ubiquitination and degradation [96]. 
The energy sensor AMP-activated protein kinase (AMPK) also negatively 
regulates SREBP-1c and SREBP-2 by preventing their processing to the mature 
form [97]. Finally, SREBPs are acetylated in the DNA-binding region by p300 and 
CBP, which stabilizes the molecules [98]. On the contrary, SIRT1 deacetylates 
SREBP-1c, eliciting its degradation [99].  
 
5. mTOR and insulin signaling pathways 
 The insulin signaling pathway is interconnected with other metabolically 
regulated networks, including the mammalian/mechanistic target of rapamycin 
(mTOR) pathway. Briefly, upon insulin binding to the insulin receptor, insulin 
receptor substrate 1 and 2 (IRS1/2) are phosphorylated on tyrosine residues. 
This sends a downstream signal that activates phosphatidylinositol 3-kinase 
(PI3K), consequently activating PDK1 (3-phosphoinositide-dependent protein 
kinase 1), which phosphorylates protein kinase B (also known as Akt) at the 
threonine 308 residue [100].  
 The mTOR pathway is activated by environmental signals in response to 
nutrient and energy demands, to regulate energy homeostasis as well as cellular 
growth and proliferation. The mTOR protein is a kinase belonging to the PI3K 
family. It exerts its function by participating in two major complexes, mTOR 
complex 1 (mTORC1) and mTOR complex 2 (mTORC2) [101]. The mTORC1 
complex contains Raptor (regulatory-associated protein of mammalian target of 
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rapamycin) and PRAS40 (proline-rich Akt substrate 40kDa), while mTORC2 is 
composed of Rictor (rapamycin-insensitive companion of mTOR) and mSin1 
(mammalian stress-activated map kinase-interacting protein 1) [101]. mTORC1, 
but not mTORC2, is inhibited by rapamycin. The mTORC1 complex is activated 
by GTP-Rheb (Ras homolog enriched in brain) [101], an indirect result of Akt 
activation (Fig. 6). Upon activation of mTORC1, the Raptor subunit interacts with 
ribosomal S6 kinase 1 (S6K1) resulting in its phosphorylation and activation 
[102]. S6K1 is an important regulator of protein translation and synthesis [103, 
104]. mTORC1 mediates insulin action to transcriptionally activate SREBP-1 
expression during fed conditions [105]. In addition, by phosphorylating and 
inactivating Lipin1, mTORC1 promotes SREBP-1 nuclear retention [106]. 
Emerging evidence is showing that mTORC1-mediated SREBP-1 upregulation is 
strictly needed for cell growth and proliferation to provide lipids for cell 
membranes [101]. In fact, SREBP-1 is becoming a novel molecular target in 
cancer [107].  
Although the upstream activators of mTORC2 remain unknown, this 
complex responds to growth factors and insulin. A main function of mTORC2 is 
to phosphorylate Akt on serine 473 [101, 108], and phosphorylation at this site is 
needed to phosphorylate and inactivate the transcription factor FoxO1, and thus, 
inhibit transcription of gluconeogenesis enzymes [109]. AktSer473 is not strictly 
needed to regulate GSK3β and TSC2 [109]. In addition, mTORC2 influences 
cytoskeleton functions by phosphorylating SGK1 (serum- and glucocorticoid-
induced protein kinase 1) and PKC (protein kinase C) [110, 111]. 
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 Upon Akt activation at Thr308 and Ser473, the transcription factor 
forkhead box O1 (FKHR or FoxO1) is inactivated through phosphorylation and 
excluded from the nucleus. In the cytoplasm, it is ubiquitinated and degraded 
[112]. FoxO1 phosphorylation results in down regulation of gluconeogenic gene 
expression and decreased hepatic glucose production. Akt activation also 
phosphorylates and inactivates glycogen synthase kinase 3 (GSK3). GSK3 is 
encoded by two genes, GSK3α and GSK3β, and among other functions, it 
inhibits glycogen synthase [113]. Thus, its phosphorylation by Akt activates 
glycogen synthase, resulting in increased glycogen biosynthesis. In addition, 
phosphorylated Akt inhibits the GTPase-activating protein heterodimer TSC1/2 
(tuberous sclerosis 1/2), an inhibitor of the mTOR pathway [101] (Fig. 6). Thus, 
insulin signaling activates mTORC1. Notably, upon mTORC1 activation by Akt, 
the former elicits a negative feedback loop to block Akt activity [114]. On one 
side, S6K1 negatively regulates IRS-1 through serine phosphorylation, which 
impairs tyrosine phosphorylation and downstream signaling [103, 104]. In 
addition, S6K1 inhibits mTORC2/Rictor activity by phosphorylating Rictor at 
Thr1135 [115] (Fig. 6).  
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Figure 6.  mTOR pathway. Insulin receptor binding triggers phosphorylation of 
Akt at T308 through PI3K and PDK1. PTEN inhibits PI3K activity. Akt indirectly 
activates mTORC1 through inhibition of TSC1/2. As a result, mTORC1 activates 
S6K and SREBP-1. In turn, S6K inhibits insulin signaling by blocking IRS1 
tyrosine phosphorylation, through a negative feedback loop. In addition, S6K 
inhibits mTORC2 activity through phosphorylation of Rictor at the Thr1135 
residue, resulting in reduced phosphorylation of Akt. These feedback 
mechanisms are important for proper signaling. Loss of this mechanism is seen 
in various cancers, with up-regulation of Akt. Source: adapted from [116].  
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6. Thesis hypothesis and research aims 
 The liver plays a significant role in glucose and lipid homeostasis. Proper 
regulation of multiple pathways, including glycolysis, lipogenesis, 
gluconeogenesis, and glycogen synthesis, are vital in preventing metabolic 
disorders associated with insulin resistance. As a result, the regulation of the 
associated gene networks must be appropriately controlled. The transcription 
factor SREBP-1 aids in enhancing expression of enzymes in the glycolysis and 
de novo lipogenesis pathways. Understanding the mechanisms by which SREBP 
regulates other pathways will be beneficial for the development of treatments of 
jus not metabolic diseases, but also cancer. Here I proposed to knock-down 
SREBP-1 in vivo and evaluate the effects on lipid and carbohydrate metabolism 
as well as insulin signaling. My overall hypothesis was that SREBP-1 regulates 
other facets of liver function, thereby connecting metabolism to cellular growth 
and proliferation. In order to test this hypothesis, two aims were pursued: 
 
1. Determine the impact of knocking-down SREBP-1 on glucose 
homeostasis in a type 2 diabetes mouse model. SREBP is highly expressed 
in human obese patients as well as in mouse models of obesity and type 2 
diabetes. Using helper-dependent adenoviral vectors, we depleted SREBP-1 in 
the liver of db/db mice and analyzed the impact on lipogenesis and carbohydrate 
metabolism.  
2. Examine the effects of silencing SREBP-1 on the insulin signaling and 
mTOR pathway. The working hypothesis was that SREBP-1 regulates several 
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molecules in this pathway, thereby influencing overall insulin signaling. In 
addition, studies resulting from the ENCODE project revealed that SREBP binds 
to the S6K1 gene. Given the role of S6K1 in regulating the insulin signaling 
pathway as well as protein synthesis and cellular growth, I depleted SREBP-1 in 
primary hepatocytes, and in the liver of normal and db/db mice, and evaluated 
the impact on mTOR and insulin signaling pathways.  
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Chapter 1: Sterol Regulatory Element Binding Protein-1 (SREBP-1) is 
required to regulate glycogen synthesis and gluconeogenic gene 
expression in mouse liver 
 
Introduction 
In the past couple of decades, the prevalence of non-alcoholic fatty liver 
disease has escalated to alarming levels. Currently, this condition affects > 30% 
of the general population [24, 117] and is as high as 75% in patients with type 2 
diabetes [26]. Hepatic lipid accumulation is associated with impaired insulin 
signaling and lack of inhibition of hepatic glucose production [30]. However, 
insulin maintains de novo lipogenesis, in a process known as selective insulin 
resistance [118]. Reduced inhibition of hepatic glucose output and increased 
lipogenesis lead to a combination of hyperglycemia and hypertriglyceridemia.  
The transcription factor SREBP-1c regulates de novo lipogenesis in the 
liver in response to increases in insulin. SREBPs are transcription factors of the 
basic helix-loop-helix leucine sipper family that are synthesized as precursors 
and bound to the endoplasmic reticulum membrane [43]. In the presence of the 
appropriate signals, SREBPs transition to the Golgi, where they are cleaved, 
releasing the mature form, which translocates to the nucleus and activates target 
gene expression [43]. SREBP-1a and SREBP-1c are isoforms of the same gene 
and transcriptionally up-regulate glycolytic and lipogenic enzymes such as L-
pyruvate kinase (Pklr), fatty acid synthase (Fasn), stearoyl-CoA desatruase 1 
(Scd1), mitochondrial glycerol-3-phosphate acyltransferase 1 (Gpam), and 
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acetyl-CoA carboxylase (Acac) [43]. In human obese patients, increased levels of 
SREBP-1c correlate with hepatic steatosis and insulin resistance [42]. Secondary 
to the hyperinsulinemia, SREBP-1c activity is higher in the liver of ob/ob and 
db/db mice, mouse models of obesity and type 2 diabetes, underscoring the role 
of this transcription factor as a contributor to hepatic steatosis and insulin 
resistance [39]. These data suggest that strategies to reduce SREBP-1 activity 
have therapeutic potential to reduce hepatic lipid accumulation and improve 
insulin sensitivity to block gluconeogenesis and hepatic glucose output. However, 
ob/ob mice lacking SREBP-1 do not exhibit improved glucose levels despite a 
significant decrease in hepatic lipid accumulation [119]. Here we have used 
helper-dependent adenoviral vectors to acutely silence SREBP-1 in the liver, to 
test the hypothesis that SREBP-1 regulates carbohydrate metabolism, in addition 
to hepatic de novo lipogenesis. Our data suggest that SREBP-1 is necessary to 
regulate carbohydrate metabolism during fed conditions. Thus, its depletion is not 
beneficial as a strategy to improve hepatic glucose output in animal models with 
hepatic insulin resistance. 
 
Materials and methods 
Helper-dependent adenoviral vector production 
Helper-dependent adenoviral vectors were generated using a Cre-loxP 
system developed by Merck Laboratories and Microbix (Toronto, Canada) [120, 
121]. These vectors are the most advanced type of adenoviral vector; they are 
devoid of viral coding sequences, and only retain the inverted terminal repeats 
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and packaging signal (Fig. 7A). The lack of viral genes eliminates the possibility 
of inducing immune responses and toxic effects, therefore leading to transgene 
expression for years, in mice and non-human primates [122, 123]. Helper-
dependent adenoviral have identical tropism to first generation adenoviral 
vectors, and predominantly transduce the liver [124, 125]. The construction of 
helper-dependent adenoviral vectors expressing a shRNA to silence SREBP-1 or 
a shRNA scrambled sequence (gAd.shSREBP1 and gAd.shSCR, respectively), 
as well as the efficacy of silencing SREBP-1 in the liver, have been previously 
described [126]. Vectors were stored at -80°C in 10 mM Tris-HCl (pH 7.5), 1 mM 
MgCl2, 150 mM NaCl, 10% glycerol. Total particle counts were determined 
spectrophotometrically, as described [126]. 
 
Animals 
SREBP-1 silencing in normal mice. Eight-to-nine-week old C57BLKS/J mice 
were given 1x1011 vp, and euthanized 7 days after adenovirus vector 
administration under ad libitum fed conditions, 24-h fasted and 24-h fasted 
followed by a 4-h re-feeding period.  
 
SREBP-1 silencing in db/db mice. Male eight-week old C57BLKS/J and db/db 
mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and 
acclimated to our facilities for a week before adenovirus administration. Animal 
care guidelines set forth by Indiana University School of Medicine were followed. 
All animals received humane care according to the criteria outlined in the Guide 
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for the Care and Use of Laboratory Animals (NIH). Mice were kept in a BSL2 
facility and had free access to a standard chow diet and water. Mice were given 
1x1011 viral particles (vp) by tail vein injection, and euthanized 3 weeks later 
under fed or 24-hour fasted conditions. Tissues were collected and snap frozen 
in liquid nitrogen or fixed in 10% buffered formalin for histology analysis.  
 
Metabolic tracer study 
Three weeks after gAd.shSREBP1 or gAd.shSCR adenoviral vector 
administration, db/db mice were given 2H2O intraperitoneally (21.4 ul/g body 
weight; this dose enriches body water content to 3%), and fasted for four hours 
with free access to water. Animals were euthanized and serum and liver were 
collected, and sent to the Mouse Metabolic Phenotyping Center at Case Western 
Reserve University for analysis. 
 
Glucose tolerance (GTT), insulin tolerance (ITT) tests  
Adenovirus vectors were administered to db/db or C57BLKS/J mice as 
described above. The GTT was performed by intraperitoneal administration of a 
bolus of glucose (1 mg/g body weight), after an overnight fast. Blood glucose was 
monitored every 30 minutes for 2 hours. For the ITT, mice were fasted for 5 
hours and given insulin intraperitoneally (1 U/kg, Human Regular Insulin, Eli 
Lilly). Blood glucose was monitored every 30 minutes for 2 hours.  
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Liver lipids 
Liver lipid analyses were carried out using ~100 mg of frozen liver tissue. 
Total liver phospholipid, triglyceride, free fatty acid and cholesterol, were 
analyzed by TLC and gas chromatography at the Mouse Metabolic Phenotyping 
Center at Vanderbilt University. In the metabolic tracer analysis, total palmitate, 
de novo palmitate, malonyl-CoA, and BHB-CoA, were analyzed by the Mouse 
Metabolic Phenotyping Center at Case Western Reserve University School of 
Medicine, as previously described [127-130]. For BHB-CoA, data are expressed 
as pmol/mg tissue relative to the internal standard [2H9]pentanoyl-CoA [129].   
 
Serum and tissue biochemistries  
Insulin levels were analyzed at the Vanderbilt Hormone Assay & Analytical 
Services Core. Blood glucose was measured every 5 days with an Ascencia 
Elite®XL meter (Bayer, Tarrytown, NY), from a drop collected from the tail vein. 
Total triglyceride in serum was determined by a triglyceride determination kit 
(Sigma Aldrich), free fatty acids with the NEFA-HR(2) kit (Wako Chemicals, 
Richmond, VA), and ß-hydroxybutyrate with a ß-hydroxybutyrate determination 
kit from Pointe Scientific (Canton, MI). All reactions were carried out in duplicate 
on uncoated, flat-bottomed 96-well plate, following the manufacturer’s 
instructions. Total liver glycogen content in tissues was determined by measuring 
amyloglucosidase-released glucose from glycogen as previously described [131]. 
Glycogen synthase fractional activity with low (0.24mM) or high (10mM) (L/H) 
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glucose-6-phosphate was assessed in total homogenates by monitoring the 
incorporation of glucose from UDP-[U-14C]glucose, as described [132]. 
 
CPT1A activity and IC50 assays 
CPT activity and malonyl-CoA sensitivity was determined using the 
radiochemical forward assay as described in detail earlier [133]. This assay is 
optimized for measuring malonyl-CoA sensitive CPT activity. The assay is carried 
out with 10 µl of a 2% liver homogenate (in physiological saline) in absence (total 
CPT activity) and presence of 200 µM malonyl-CoA (malonyl-CoA insensitive 
activity) at 37°C. The difference in velocity represents CPT1A activity. The 
malonyl-CoA sensitivity was assessed by measuring the activity in the presence 
of 8.0 µM malonyl-CoA that under the experimental conditions corresponds to the 
approximate IC50 value for malonyl-CoA in mouse liver homogenates. All values 
were corrected by subtracting the malonyl-CoA insensitive values. The remaining 
activity upon incubation with 8 µM malonyl-CoA is plotted.  
 
Western blotting 
To generate liver whole cell protein extracts, 100 mg of frozen liver was 
homogenized in lysis buffer with protease and phosphatase inhibitors (50 mM 
HEPES pH 7.5, 2 mM EGTA, 2 mM EDTA, 150 mM NaCl, 10 mM NaF, 10% 
glycerol, 0.1% Nonidet™ P-40, 20 mM β-glycerolphosphate, 2 mM sodium 
pyrophosphate, 1 mM sodium vanadate, and TLCK 0.1 mM protease inhibitors, 2 
mM benzamidine, 0.5 mM PMSF and 10 µg/ml leupeptin). Liver extracts were 
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centrifuged at 13,000 rpm, the fat layer carefully aspirated, and the supernatant 
collected for use in Western blotting. NE-PER (Thermo Scientific, Rockford, IL) 
extraction reagents and protease inhibitor cocktails (Thermo Scientific) were 
used to isolate liver nuclear and cytoplasmic proteins according to the 
manufacturer’s recommendations. Proteins were separated by PAGE and 
transferred to 0.2 mm PVDF membranes (Bio-Rad). Membranes were blocked 
with 5% dry milk-TBST or 5% BSA-TBST for 1-2 hours and incubated with the 
following antibodies:  SREBP1 and tubulin-α (Thermo Scientific), Lamin A/C, 
ACAC, phospho-ACAC, phospho-glycogen synthaseS641 and glycogen synthase 
(Cell Signaling), Topo II (Abcam), CPT1A and CPT2 [kind gift from Dr. Carina 
Prip-Buus (INSERM, U1016, Institut Cochin, Paris, France)]. Blots were 
developed with Pierce ECL blotting substrate (Thermo Scientific) and exposed to 
ECL film (GE Healthcare, Piscataway, NJ).  
 
Real-time RT-PCR  
Total RNA was isolated from frozen liver samples (Qiagen). qRT-PCR was 
carried out in an ABI 7500 instrument (Applied Biosystems, Foster City, CA), 
using 50 ng of RNA and the QuantiTect SYBR Green RT-PCR Kit (Applied 
Biosystems). Primer pairs were purchased from Qiagen, or designed to bind 
different exons of the gene and amplify fragments of approximately 200 bp, and 
were first confirmed to yield a single band of the expected size by agarose gel 
electrophoresis, as well as a negative result in wells containing sample without 
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reverse transcriptase. Primer sequences are available upon request. The relative 
quantification of each gene was normalized with Cyclophilin A. 
 
Statistics 
Numerical values represent mean ± SD. P values were calculated using 
unpaired two-tailed Student’s t-tests. A P value of less than 0.05 was considered 
statistically significant. 
 
Results 
Silencing SREBP-1 increases experession of gluconeogenesis genes and 
reduced glycogen accumulation 
To study the effects of silencing SREBP-1 on carbohydrate metabolism 
during the transition between the fed and fasted, helper-dependent adenoviral 
vectors expressing and shRNA to target SREBP-1 (gAd.shSREBP1) or a 
scrambled shRNA (gAd.shSCR) were injected into the tail vein of normal mice 
(Fig. 7, A and B). No alteration in blood glucose levels were observed between 
the two treatments (Fig. 7C). However, glycogen accumulation was reduced by 
30% under fed conditions (Fig. 7C). In addition, normal mice that received 
gAd.shSREBP1 has lower levels of glycogen synthase 2 (GYS2) protein (Fig. 
7D). Furthermore, STREBP-1 deficiency increased expression of the 
gluconeogenesis enzyme phosphoenolpyruvate carboxykinase (PCK1) (Fig. 7D). 
These data indicate that SREBP-1 is needed to appropriately regulate glycogen 
synthesis and to block Pck1 expression. 
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Figure 7.  Impact of SREBP-1 knock-down on carbohydrate metabolism in 
normal mice. Groups of five C57BKS mice were given 1x1011 vp gAd.shSCR or 
gAd.shSREBP1 and euthanized one week later under fed or 24-h fasted 
conditions. (A) Helper-dependent adenovirus vector used to express shRNA. 
Hairpin RNA expression was driven by the U6 promoter. ITR, inverted terminal 
repeat; ψ, packaging signal. (B) SREBP-1 precursor (p-SREBP) or nuclear (n-
SREBP) protein levels. (C) Blood glucose was not affected by SREBP-1 
silencing. However, glycogen levels were significantly lower under fed and fasted 
conditions in mice treated with gAd.shSREBP1; *p<0.05; n=5-6. (D) Immunoblots 
to detect GYS2, P-GYS2, PCK1 and tubulin. 
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SREBP-1 knockdown reduced steatosis in an animal model of hepatic insulin 
resistance 
SREBP-1 activity is higher in the liver of db/db mice, and animal model of 
obesity with hepatic steatosis and severe insulin resistance. Thus, depleting 
SREBP-1 was expected to diminish lipogenesis and improve steatosis and 
consequently, improve insulin resistance. As predicted, silencing SREBP-1 
resulted in down-regulation of hepatic de novo lipogenesis genes Fasn, Scd1, 
and Gpam (Fig. 8A). Interestingly, Acacb mRNA and protein expression were 
dramatically blunted, whereas Acaca mRNA, protein, and protein 
phosphorylation were not changed relative to the db/db control group (Fig 8, A 
and B). These data indicate that SREBP-1 is an important regulator of ACACB 
and that SREBP-1 is not critical to maintain high ACACA levels in db/db mice.  
 Silencing SREBP-1 resulted in lower liver triglyceride levels in the db/db 
gAd.shSREBP1 group compared with the gAd.shSCR under fasting condition 
(Fig. 8C). Using 2H2O as a metabolic tracer, de novo liver palmitate and total liver 
palmitate were found to be reduced 70 and 30%, respectively, confirming that 
down-regulation of enzymes in the lipogenesis pathway resulted in reduced 
levels of glucose conversion into lipid (Fig. 9A) The decline in de novo 
lipogenesis (as well as in ACAC levels) was expected to decrease malonlyl-CoA, 
an allosteric inhibitor of CPT1A. CPT1A is the enzyme that transfers an acyl 
group from CoA to carnitine, which is then translocated into mitochondria for 
oxidation. Lower malonyl-CoA levels were expected to increase CPT1A activity 
and subsequently, enhance fatty acid oxidation (FAO).  
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Figure 8.  SREBP1 silencing in db/db mice. Groups of eight db/db mice were 
given 1x1011 vp gAd.shSCR or gAd.shSREBP1 through the tail vein, and 
euthanized three weeks later under fed (ad libitum) or 24-hour fasted conditions. 
Groups of four normal C57BLKS mice were used as controls and received the 
same dose of gAd.shSCR adenovirus. (A) Effect of silencing SREBP1 on 
lipogenic enzyme expression. Data are presented as mean ± SD. *p<0.05 versus 
control; n=7-8. (B) Immunoblot analysis for SREBP-1 precursor (p-SREBP) or 
nuclear (n-SREBP) protein, ACAC and phosphorylated ACAC (P-ACAC), three 
weeks after gAd.shSCR or gAd.shSREBP1 administration. ACAC and P-ACAC 
panels show ACACA as a bottom 265 kDa band and ACACB as a top 280 kDa 
band. (C) Hepatic triglyceride levels in db/db mice; *p<0.05 versus control; n=8. 
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 As anticipated, malonyl-CoA levels were depleted to near half the levels 
observed in control animals (Fig. 9A). We confirmed that CPT1A and CPT2 
protein levels were not changed between gAd.shSCR and gAd.shSREBP1-
treated mice, under fed or 24-h fasting conditions (Fig. 3B), and no difference 
was observed in CPT1A IC50 values for malonyl-CoA between the two groups, 
suggesting similar capacity to be inhibited by this metabolite (Fig. 9B). 
Nevertheless, no evidence of increased FAO was observed in the 
gAd.shSREBP1-treated group, based on serum β-hydroxybutyrate and liver 
BHB-CoA levels (Fig. 9, A and C). Overall, these data suggest that SREBP-1 
deficiency had a positive impact on hepatic steatosis, most likely as a result of 
reduced lipogenesis rather than increased FAO. 
 Serum triglyceride levels were found mildly elevated in SREBP-1 depleted 
mice compared with diabetic controls under fasting conditions (Table1), and this 
correlated with a significant reduction of LDL receptor mRNA (Fig. 9D), indicating 
decreased uptake of lipoproteins by the liver. The importance of SREBP-1a as a 
regulator of the low density lipoprotein receptor and its control of lipoprotein 
uptake/degradation in the liver has been highlighted in transgenic mice 
overexpressing SREBP-1a in this tissue, which display markedly increased levels 
of LDL receptor [134]. Whereas null Ldlr mice accumulate triglyceride and 
cholesterol in serum, mice overexpressing SREBP-1a do not accumulate these 
metabolites in plasma because they are degraded through the action of LDL 
receptors [134]. Furthermore, transgenic mice overexpressing SREBP-1a or 
SREBP-1c in liver have significantly higher levels of triglycerides in liver and 
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lower levels in serum [52]. Likewise, adenovirus-mediated SREBP-1c 
overexpression in liver induced a 2-fold increase in hepatic triglyceride levels and 
up-regulation of LDL-receptor, leading to reduced serum levels of triglycerides 
[135]. 
 
 
Table 1. Effect of SREBP-1 silencing on weight and serum chemistries 
 db/db WT 
gAd.shSCR  gAd.shSREBP  gAd.shSCR 
Total body weight (g) 44.7 ± 1.92** 40.3 ± 3.65*,** 22.7 ± 1.32 
Fed     
Liver weight (g)  2.63 ± 0.22 1.83 ± 0.18* 1.10 ± 0.06 
Serum FFAs  (mM) 1.55 ± 0.27** 2.23 ± 0.28*,** 0.96 ± 0.06 
Serum TG (mg/ml) 1.17 ± 0.27** 1.41 ± 0.44** 0.75 ± 0.06 
Fasted     
Liver weight (g)  2.18 ± 0.20 1.46 ± 0.16* 0.86 ± 0.05 
Serum FFAs  (mM) 1.32 ± 0.22 2.05 ± 0.14*,** 1.25 ± 0.1 
Serum TG (mg/ml) 0.63± 0.08 1.01 ± 0.11*,** 0.74 ± 0.1 
    
Mice were treated as described in the legend of Fig. 1. *p<0.05 db/db 
gAd.shSREBP1 versus gAd.shSCR; **p<0.05 compared to WT. n=8 db/db, n=4-
5 WT.  
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Figure 9.  
SREBP-1 silencing decreases de novo lipogenesis. (A) Groups of 8 db/db 
mice were administered 1x1011 vp gAd.shSCR or gAd.shSREBP1. Three weeks 
later, 2H2O was administered intraperitoneally. Mice were fasted for 4 hours and 
euthanized. Total palmitate, de novo synthesis of palmitate, malonyl-CoA and 
BHB-CoA were analyzed (p<0.05 vs control; n=8). (B) Mice were treated as 
described in Fig. 8. CPT1A and CPT2 protein levels under fed and fasted 
conditions, and CPT1A sensitivity to malonyl-CoA in livers of mice fasted for 24-
hours; n=5. (C) Mice were treated as described in Fig. 2. β-hydroxybutyrate 
serum levels; n=4-5 WT, n=8 db/db. (D) LDL receptor mRNA expression in db/db 
mice; n=7-8. 
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Increased expression of gluconeogenesis genes and lower glycogen 
accumulation in SREBP-1 depleted db/db mice 
 Despite lower liver steatosis, acutely silencing SREBP-1 in db/db mice 
had no impact on glucose and insulin levels (Fig. 10A). Furthermore, mice were 
slightly more hyperglycemic upon a 24-h fast, suggesting a defect in the 
regulation of glucose homeostasis. To determine the impact of silencing hepatic 
SREBP-1 on glucose tolerance, glucose and insulin tolerance tests were 
performed. Consistent with the lack of glucose reduction, no differences between 
the gAd.shREBP1- and the gAd.shSCR- treated groups were observed (Fig. 
10B). Thus, hepatic SREPB-1 silencing has no major impact on whole body 
glucose tolerance. 
To investigate the basis of the lack of improvement in glucose 
homeostasis, glycogen accumulation was measured. Remarkably, SREBP-1 
silencing resulted in ~ 50% lower glycogen levels under fed conditions, compared 
with db/db control mice, as previously seen in normal mice (Fig. 11A). In addition, 
glycogen synthase 2 (GYS2) mRNA, glycogen synthase activity, and protein 
levels were decreased, relative to diabetic control mice (Fig. 11, B-D). These 
observations were recapitulated in another animal model of obesity and type 2 
diabetes, the ob/ob mouse (data not shown). 
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Figure 10. SREBP-1 silencing does not improve whole body glucose or 
insulin tolerance. Mice were treated as described in Fig. 2. (A) Glucose and 
insulin levels in serum; n = 5-8. (B) A glucose tolerance test (GTT) was 
conducted after overnight fast and intraperitoneal administration of a glucose 
bolus (1 mg/g body weight); an insulin tolerance test (ITT) was carried out after 
fasting animals for 5 hours and intraperitoneal administration of human regular 
insulin (1 U/kg); n=7 db/db, n=5 WT.  
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Figure 11. SREBP-1 silencing alters gluconeogenesis and glycogen 
synthesis. db/db mice were treated as described in Fig. 8. (A) Hepatic glycogen 
content in db/db mice; n=8. (B) Glycogen synthase 2 mRNA levels; n=7-8. (C) 
Immunoblot analysis of total and phosphorylated glycogen synthase. (D) Ratio of 
the glycogen synthase activity measured with low (L) over high (H) glucose-6-
phosphate, under fed and fasted conditions; n=3; *p<0.05 vs control. 
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To further understand the role of SREBP-1 at regulating carbohydrate 
metabolism, we analyzed expression of limiting enzymes in the glycolysis and 
gluconeogenesis pathways, including glucokinase (Gck), liver-pyruvate kinase 
(Pklr), phosphoenolypyruvate carboxykinase (Pck1), and glucose-6-phosphatase 
(G6pc). SREBP-1 overexpression has been shown to induce glucokinase gene 
expression [135]. Thus, lack of SREBP-1 was expected to reduce its levels, 
which could have affected glycogen synthesis. Gck levels were not altered upon 
SREBP-1 silencing (Fig. 12A). However, Pklr gene expression was severely 
blunted compared with diabetic control animals, indicating reduce activity of the 
glycolysis pathway (Fig. 12A). In contrast, gluconeogenesis genes Pck1 and 
G6pc were significantly higher in the gAd.shSREBP1- treated group. PCK1 
mRNA levels were >2-fold higher, both under fed and fasting conditions, and 
protein levels were also increase (Fig. 12, A and B). Overall, our data suggest 
that increased PCK1 levels, reduced PKLR activity, and reduced glycogen 
storage capacity may have accounted for lack of improved glycemia in the 
gAd.shSREBP1- treated db/db animals (Fig. 10A). 
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Figure 12. SREBP-1 silencing alters gluconeogenesis and glycogen 
synthesis. Mice were treated as described in Fig. 8. (A) Gck, Pklr, Pck1, G6pc 
mRNA expression; n=7-8. (B) PCK1 protein levels.  
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Discussion 
 Hepatic fat accumulation is strongly associated with insulin resistance and 
inappropriate inhibition of hepatic glucose output. A large amount of literature has 
linked high SREBP1 activity with insulin resistance and type 2 diabetes. A variety 
of gene ablation as well as insulin-sensitizing drug studies have shown 
concomitant reductions in SREBP-1 and insulin resistance. For example, it has 
been suggested that the beneficial effects of resveratrol and other polyphenols 
on hepatic steatosis and insulin sensitivity is mediated by AMPK, which 
phosphorylates and inactivates SREBP-1 [97]. Recently, it has been proposed 
that multiple nuclear receptors, including ERα, CAR, LRH-1, TRβ, and FXR/SHP, 
exert their antidiabetic effects through down-regulation of SREBP-1 [136], placing 
this transcription factor at the crossroads between steatosis and hepatic insulin 
resistance. Nevertheless, these studies are in contrast with data generated in 
leptin-deficient (ob/ob) SREBP-1 whole body knock-out mice [119]. Lepob/ob x 
Srebp-1-/- mice remain hyperglycemic despite a 50% decrease in hepatic lipid 
accumulation [119]. Given that this study did not provide a mechanism for the 
lack of improvement in insulin resistance, we hypothesized that SREBP-1 may 
play a role in other aspects of liver metabolism. Thus, we knocked down SREBP-
1 in normal mice and in db/db mice to clarify the role of this transcription factor on 
carbohydrate metabolism as well as investigate the therapeutic value of silencing 
SREBP-1 in the liver of a mouse model with established steatosis and severe 
insulin resistance. This is the first comprehensive in vivo study addressing both 
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carbohydrate and lipid metabolism and the only adult model of hepatic SREBP-1 
deficiency in normal and obese mice.  
 The results of this study have underscored the requirement for SREBP-1 
in glycogen synthesis in the fed state. SREBP-1 deficiency in db/db mice 
decreased glycogen levels as well as glycogen synthase mRNA, protein, and 
enzyme activity during fed conditions, when glycogen synthesis take place. 
These observations were also observed in normal mice, implying that SREBP-1 
is needed to regulate glycogen metabolism appropriately. The effects on 
glycogen were independent from glucokinase gene expression, which was 
unaffected by SREBP-1 silencing. Glucokinase gene expressin has been shown 
to be up-regulated in response to SREBP-1c overespression [135], although 
other studies have shown that increases in SREBP-1c were neither necessary 
nor sufficient to induce glucokinase [137, 138]. Our study confirms that in vivo, 
SREBP-1 is dispensable for expression of this gene.  
 In addition to alterations in glycogen synthesis, up-regulated Pck1 and 
G6Pase gene expression was observed under fed and fasted conditions. In vitro 
studies have previously demonstrated that SREBP-1 negatively regulated Pck1 
gene expression by binding to two sterol regulatory elements present in the 
promoter of the gene [139]. SREBP-1 has also been shown to inhibit Pck1 gene 
transcription by interacting with HNF4α and interfering with recruitment of the 
transcription co-activator PGC-1α to the Pck1 promoter [140]. Here we show that 
in vivo, SREBP-1 deficiency results in lack of appropriate inhibition of Pck1 and 
G6pase gene expression. Finally, Pklr was found severely diminished. Overall, 
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this study provides evidence that SREBP-1 controls carbohydrate metabolism 
during fed conditions by promoting glycogen synthesis, enhancing glycolysis, and 
inhibiting gluconeogenic gene expression. 
 The importance of the de novo lipogenesis pathway as a contributor of 
hepatic steatosis has been underscored in a study using metabolic tracers in 
human patients with non-alcoholic fatty liver disease [36]. In these individuals, as 
much as 26% of triglycerides are derived from this pathway [36]. In addition, de 
novo lipogenesis is elevated in the fasted state and does not increase 
postprandially, indicating that one of the underlying causes of hepatic steatosis in 
non-alcoholic fatty liver disease might be the inability of the liver to regulate this 
pathway appropriately [36]. As expected, SREBP-1 silencing resulted in 
decreased expression of de novo lipogenesis genes, including Fasn, Acacb, 
Gpam, and Scd1. Consistent with the decrease in gene expression, de novo 
synthesis of palmitate was 70% lower in livers of gAd.shSREBP1-treated animals 
relative to control db/db mice, and liver triglycerides were significantly decreased 
under fasting conditions. This indicates that, as observed in human with non-
alcoholic fatty liver disease [36], enhanced de novo lipogenesis in the fasted 
state is one of the underlying causes of hepatic lipid accumulation in db/db mice 
and targeting SREBP-1 lowered steatosis. 
 ACACB co-localizes spatially with CPT1A on the mitochondrial membrane 
[141], and it has been suggested that the malonyl-CoA produced from this 
isoform inhibits CPT1A activity and FAO, whereas the malonyl-CoA produced by 
ACACA is used to generate palmitate [141]. Nevertheless, liver-specific Acaca-
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deficient mice compensate for lack of ACACA by increasing ACACB expression 
and maintain physiological levels of de novo lipogenesis and FAO, suggesting 
that compartmentalization of malonyl-CoA produced by each ACAC isoform is 
not stringent [142]. Increased activities of transcription factors SREBP-1 and 
carbohydrate-responsive element-binding protein (ChREBP) have been 
observed in db/db and ob/ob mice, animal models of obesity and type 2 diabetes. 
Silencing ChREBP in liver of ob/ob mice resulted in significant reduction in 
ACACA and ACACB, de novo lipogenesis and triglyceride levels, as well as 
increased serum levels of β-hydroxybutyrate, which was attributed to higher FAO 
rates [40]. In contrast, SREBP-1 silencing in db/db mice largely reduced ACACB, 
but had no effect on ACACA, the predominant isoform in liver. Serum β-
hydroxybutyrate levels were not elevated under fed or 24-h fasting conditions. 
Furthermore, the levels of liver BHB-CoA, an intermediate of fatty acid oxidation 
[130, 143], were not significantly different between the two groups. Given that 
SREBP-1 silencing did not reduce ACACA, these data suggest that both 
isoforms need to be diminished to reduced malonyl-CoA to levels that allow 
increasing CPT1A activity. Thus, depleting SREBP-1 in db/db mice reduced 
lipgenesis, but FAO was not enhanced. 
 A growing number of studies are reporting a dissociation between hepatic 
steatosis and insulin resistance [144-146]. Overexpression of diacylglycerol O-
acyltransferase 2 (DGAT2) in the liver increased triglyceride, ceramide, and 
diacylglycerol without alteration on insulin or glucose tolerance [145]. Gpam 
deficiency in ob/ob mice diminished SREBP-1 levels with a concomitant 
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decrease in hepatic triglyceride accumulation, but no improvement in hepatic or 
peripheral insulin sensitivity [146]. Furthermore, fasting glucose was 
exacerbated, whereas the absence of Gpam in lean mice had no effect on 
glucose, similar to what we observed in gAd.shSREBP1-treated db/db and lean 
mice, respectively. SREBP-1 silencing is another example of dissociation 
between hepatic steatosis and glucose tolerance. Our data provide evidence of 
additional roles for SREBP-1 at regulating metabolism besides its established 
function at facilitating lipogenesis. Thus, SREBP-1 coordinates changes in gene 
expression physiologically important during the fed state: enhancing de novo 
lipogenesis and glycogen synthesis, facilitating glycolysis, and inhibiting 
gluconeogenesis. 
 In conclusion, this work provides evidence of novel roles for SREBP-1, a 
critical transcription factor that has been extensively associated with hepatic 
steatosis and insulin resistance. Our data indicate that SREBP-1 depletion has 
profound effects on expression of genes needed for carbohydrate metabolism. 
Hence, the benefits of reducing de novo lipogenesis in db/db mice were offset by 
the negative impact of gluconeogenesis and glycogen synthesis. 
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Chapter 2: Insulin resistance and hepatic steatosis in primary hepatocytes 
 
Introduction 
 Due to the strong association between fatty acid accumulation and 
impairment of the insulin signaling pathway, multiple strategies are being 
pursued to reduce hepatic steatosis with the goal of improving insulin sensitivity. 
We have shown in Chapter 1 that silencing SREBP-1 in db/db mice reduces 
steatosis largely as the result of decreased DNL [147]. Contrary to our 
expectations, no evidence of increased fatty acid oxidation was observed, 
despite the fact that malonyl-CoA levels were significantly reduced [147]. Thus, 
additional studies are needed to investigate the underlying mechanisms leading 
to this observation, and to better understand whether CPT1A activity or the 
capacity of mitochondria to oxidize fatty acids is limiting in the db/db mouse 
model and in insulin resistant states. There is evidence showing that 
phosphorylation also influences CPT1A activity, although its regulation under 
pathophysiological conditions remains unknown [148]. It is also known that 
hyperinsulinemia reduces mitochondrial biosynthesis in hepatocytes [149]. Thus, 
we focused on setting up conditions to study whether increasing CPT1A activity 
by adenovirus-mediated overexpression of CPT1A would improve fatty acid 
oxidation under insulin resistance conditions.  
There is evidence from the literature supporting the idea that CPT1A 
activity in insulin resistant states may be limiting and increasing it may be 
beneficial. Studies performed in adipocytes by Gao and colleagues demonstrated 
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that increasing human carnitine palmitoyl-transferase 1A (CPT1A) activity 
resulted in the down regulation of c-JNK as well as lipid derivatives [150]. 
Furthermore, insulin resistance was improved in both adipocytes and myocytes, 
suggesting that expressing CPT1A is beneficial to increase insulin sensitivity in a 
high fatty acid environment [150]. In the liver, two separate in vivo studies 
revealed diverging results regarding the use of CPT1A as a strategy to reduce 
hepatic steatosis and improve insulin resistance. Orellana-Gavaldà and 
colleagues demonstrated that high-fat fed mice overexpressing wild type CPT1A 
or a mutated form of CPT1A not sensitive to malonyl-CoA inhibition, decreases 
lipid accumulation and improves insulin resistance [151]. However, Monsénégo 
and colleagues showed that overexpressing malonyl-CoA-insensitive CPT1A, 
improved insulin signaling but failed to reduce triglyceride accretion in the liver of 
high-fat fed and ob/ob mouse models, suggesting a disconnection between 
insulin resistance and hepatic steatosis [152]. A couple of factors could have 
influenced the results of these studies that may explain the discrepancies 
between them. The Orellana-Gavaldà’s group injected the vector expressing 
CPT1A two weeks after starting the high-fat diet treatment, which is unlikely to 
have been sufficient time to develop insulin resistance and hepatic steatosis. 
Mice were examined 3 months later [151]. Thus, this study focused on preventing 
insulin resistance, rather than treating it with CPT1A overexpression. On the 
contrary, Monsénégo’s group conducted the study after the onset of steatosis 
and insulin resistance (20 weeks after high-fat feeding), which allowed testing 
whether CPT1A overexpression is a useful therapy for the treatment of steatosis 
58 
and insulin resistance [152]. Nevertheless, the authors concluded that the 
therapy improves insulin sensitivity but does not reduce steatosis. Given that 
their studies only lasted 2 weeks, this may have been insufficient time to reduce 
fatty acid buildup. These results suggest that CPT1A may have a fundamental 
role in the prevention of lipid accumulation and insulin resistance, while it may 
not be effective at treating this condition. 
These data underscored the importance of defining a mechanism for how 
insulin resistance is prompted by hyperinsulinemia and lipid accumulation 
independent of one another. Studying hepatocytes under hyperinsulinemic or 
hyperlipidemic conditions separately may help further our knowledge on how 
each plays a role in the development of insulin resistance. Here, I evaluated the 
effects of overexpressing CPT1A using helper dependent adenoviral vectors in 
primary hepatocytes under each condition separately to better understand the 
mechanisms by which CPT1A may improve insulin signaling. The data indicate 
that insulin signaling was not improved by CPT1A overexpression regardless of 
the conditions used to induce insulin resistance. Although CPT1A alone cannot 
improve insulin signaling in primary hepatocytes, possibly due to the fact that 
primary cells can be cultured for only a short time, CPT1A overexpression may 
still be a viable therapeutic tool for NAFLD treatment. Moreover, the assays and 
techniques used to induce insulin resistance will be useful for future studies on 
mechanisms of insulin resistance development in the liver. This system could be 
used to further study the molecular mechanisms by which silencing SREBP-1 
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does not lead to improved fatty acid oxidation, and the possible impact of 
hyperinsulinemia on CPT1A phosphorylation and activity. 
 
Materials and methods 
Generation of adenoviral vectors expressing wild type or mutant CPT1A 
Total rat liver RNA was used to generate CPT1A cDNA (High Capacity 
cDNA reverse transcription kit, Applied Biosystems, Life Technologies, Grand 
Island, NY). The following oligonucleotides were used to amplify CPT1A:  
5’-TATGCAGAATTCCAATAGGTCCCCACTCAAGATGG-3’ and 5’-
AATCAGGATATCTTACTTTTTAGAATTGATGGTGAGGC-3’. Wild type CPT1A 
(CPT1-WT) cDNA was cloned into the pBluescript II SK(+) plasmid (Agilent 
Technologies). Changing methionine 593, a critical residue for malonyl-CoA 
inhibition, to a serine, results in constitutively active CPT1A [153]. A constitutively 
active mutant CPT1A (CPT1A-Mu) was generated using these oligonucleotides: 
5’-CTCACATATGAGGCCTCCTCAACCCGGCTCTTCCGAGAA-3’ and 5’-
TTCTCGGAAGAGCCGGGTTGAGGAGGCCTCATATGTGAG-3’ with site 
directed mutagenesis (Agilent Technologies, Quick Change II Site-directed 
Mutagenesis Kit, Santa Clara, CA). The cDNA sequence was confirmed by 
sequencing. Expression cassettes were then generated in which the cDNAs were 
under the control of the elongation factor 1-α (EF1-α) promoter. This promoter 
was used because it results in moderately high levels of expression and does not 
shut down in the liver, allowing long-term expression of CPT1A. The bovine 
growth hormone polyA signal was cloned downstream of the cDNA using the 
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following oligonucleotides: 5’-
TATGCAGATATCCTAGAGCTCGCTGATCAGCCTC-3’ and 5’-
AATCAGAAGCTTCCATAGAGCCCACCGCATCCC-3’. Helper-dependent 
adenoviral vectors were generated using a Cre-loxP system (Microbix 
Biosystems Inc., Toronto, Canada) as previously described [154]. Briefly, the 
expression cassettes were cloned into pRES, and the resulting plasmids were 
digested with Hind III. Simultaneously, plasmid pC4HSU [121] was digested with 
Asc I. Escherichia coli BJ5183 cells were co-transformed with the linearized 
plasmid (100 ng) and each of the Hind III fragments (300 ng), as described [155]. 
Recombination between homologous regions in these plasmids generated the 
helper-dependent adenovirus constructs containing the expression cassettes. To 
rescue helper-dependent adenoviral vectors, plasmids containing expression 
cassettes were digested with Pme I. HEK293Cre4 cells were transfected with 5 
µg of Pme I-digested DNA. Twenty-four hours later, helper H14 was added at 
MOI 3, and cells were collected after the onset of cytopathic effect (CPE). 
Helper-dependent adenoviral vector amplification was achieved by passaging 
lysates in 6-cm dishes (5x106 cells/dish). For large-scale vector amplification of 
gAd.CPT1A and gAd.Mu-CPT1A, 16 x 500 cm2 flasks (~1x109 cells total) were 
used. The virus was purified by one CsCl step gradient centrifugation followed by 
one CsCl isopycnic separation. The helper-dependent adenovirus band was 
collected and dialyzed in TMN buffer [10 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 150 
mM NaCl, 10% glycerol], and stored at -80°C. 
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Primary hepatocyte isolation 
Primary hepatocytes were isolated by collagenase digestion from male 
C57BL/6J mice, as previously described [98]. Briefly, mice were anesthetized by 
pentobarbital. The portal vein was cannulated with a 22-gauge intravenous 
catheter and the liver was perfused with Ca2+, Mg2+-free Hanks’ buffer solution 
containing 0.5 mM ethylene glycol-bis-(2-aminoethylether) N,N,N’,N’-tetracetic 
acid (EGTA), and 0.05 M N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid 
(HEPES, pH 7.4). This was followed by collagenase perfusion containing 0.05 M 
HEPES and 0.04% collagenase type IA. Primary hepatocytes were plated at a 
density of 6x105 cells/well in 2 mL of DMEM with 10% FBS, 1 nM 
dexamethasone, and 100 IU/mL/ penicillin and 100 ug/mL streptomycin (P/S) on 
a 6-well plate.  After 4 hours medium was changed to 2 ml/well of DMEM with 5% 
FBS, 1 nM dexamethasone, and 100 IU/mL P/S. 
 
Hyperinsulinemia-induced insulin resistance 
Prevention studies: Primary hepatocytes were infected with gAd.CPT1A-WT, 
gAd.CPT1-Mu, or gAd.NEC virus at MOI 6, 4 hours after plating. Medium was 
changed to DMEM containing 4.5 g/L glucose, supplemented with 5% FBS, 1 nM 
dexamethasone, and 100 IU/mL / 100 ug/mL penicillin/streptomycin (1x P/S). 
Twenty-four hours later, cells were treated with 5 nM insulin to induce insulin 
resistance. An insulin-sensitive control group was infected with gAd.NEC and 
vehicle was added to the medium. Medium with/out insulin was replaced every 
24 hours. Seventy-one hours after infection, all cells were cultured in medium 
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without serum and insulin for 30 minutes to fast cells. To evaluate insulin 
sensitivity, each group was divided in two and received either 20 nM of insulin or 
vehicle for 30 minutes and then harvested. 
 
Treatment studies: Hepatocytes were treated with DMEM containing 4.5g/L 
glucose, supplemented with 5% FBS, 1 nM dexamethasone, and 1x P/S, 
supplemented with either 5 nM insulin or vehicle. Twenty-four hours after insulin 
or vehicle treatment, cells were infected with gAd.CPT1A-WT, gAd.CPT1A-Mu, 
or gAd.NEC virus at MOI 15 for 4 hours in regular medium (DMEM with 5% FBS, 
1 nM dexamethasone, and 1x P/S). Medium was replaced with 5 nM insulin-
containing medium or vehicle, and changed every 24 hours. Forty-seven hours 
post infection all cells were cultured in medium without serum and insulin for 30 
minutes to fast cells. To evaluate insulin sensitivity, each group was divided in 
two and received 20 nM of insulin or vehicle for 30 minutes and then harvested. 
 
Hyperlipidemia-induced insulin resistance 
Prevention studies: Primary hepatocytes were infected with gAd.CPT1A-WT, 
gAd.CPT1A-Mu, or gAd.NEC virus at MOI 30.  Medium was changed to serum-
depleted DMEM containing 4.5 g/L of glucose, for 4 hours.  To induce steatosis 
and insulin resistance, cells were incubated with serum depleted DMEM 
supplemented with 0.4 mM palmitate (PA) conjugated with BSA, for 6 hours at 
37°C. One plate was infected with gAd.NEC and treated with medium containing 
only BSA as a control group (insulin-sensitive). Medium was replaced with 
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DMEM and 1x P/S after the 6 hours. Forty-seven hours after infection, each 
group was divided in two and received 20 nM of insulin or vehicle to evaluate 
insulin sensitivity. Cells were harvested 30 minutes later. 
 
Treatment studies: Hepatocytes were incubated in serum depleted DMEM 
containing 4.5 g/L glucose and 1x P/S supplemented with 0.3 mM palmitate 
conjugated with BSA overnight to induce insulin resistance. Cells were infected 
with gAd.CPT1A-WT, gAd.CPT1A-Mu, or gAd.NEC virus at MOI 30 for 4 hours 
the next day, following another incubation with DMEM and 1x P/S supplemented 
with 0.3 mM/BSA for another 24 hours. One plate was used as a control and 
treated only with BSA. Twenty-eight hours post-infection, each group was divided 
in two and received 20 nM of insulin or vehicle to evaluate insulin sensitivity. 
Cells were harvested 30 minutes later. 
 
Conjugation of BSA/palmitate  
A 6:1 molar ration of palmitate:BSA solution was made (1 mM sodium 
palmitate/0.17 mM BSA). Fatty acid free BSA (Sigma-Aldrich, St. Louis, MO) was 
dissolved in 150 mM NaCl solution at 37°C, while sodium palmitate (Sigma-
Aldrich, St. Louis, MO) was dissolved in 150 mM NaCl solution at 70°C. Half of 
the BSA solution was combined with the palmitate solution in equal parts (1:1) 
and incubated for 1 hour at 37°C to conjugate; pH was adjusted to 7.4. A 150 
mM NaCl solution was added to the other half of the BSA solution in equal parts 
to make the BSA control solution. 
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Western blotting 
Whole cell protein lysates were generated through homogenization in RIPA 
buffer (25 mM Tris•HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium 
deoxycholate, 0.1% SDS; Thermo Scientific, Rockford, IL) containing protease 
and phosphatase inhibitors (Roche, Indianapolis, IN). Proteins were separated by 
PAGE electrophoresis and transferred to 0.2-mm PVDF membranes (Bio-Rad). 
Membranes were blocked with 5% BSA-TBST or 5% dry milk-TBST for 1-2 h and 
incubated with the following antibodies: AktSer473 and Akt (Pan); Foxo1Ser256 and 
Foxo1 (Cell Signaling, Boston, MA); CPT1A [kind gift from Dr. Carina Prip-Buus, 
(INSERM, U1016, Institut Cochin, Paris, France)]; β-actin (Santa Cruz 
Biotechnology, Dallas, TX); and Tubulin-α (Thermo Scientific, Rockford, IL). Blots 
were developed using Pierce ECL blotting substrate (Thermo Scientific) and 
exposed to film (GE Healthcare). 
 
Statistics 
Numerical values represent mean ± S.D. P values were calculated using 
unpaired two-tailed Student’s T-tests. A P value of <0.05 was considered 
statistically significant. 
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Results 
CPT1A overexpression in primary hepatocytes does not rescue insulin resistance 
induced by hyperinsulinemia 
Helper-dependent adenoviral vectors expressing wild type CPT1A (gAd.CPT1A-
WT) or mutated CPT1A (gAd.CPT1A-Mu) under the control of the elongation 
factor 1α promoter, were generated as described in the Materials and methods 
section. HEK293 cells and primary hepatocytes were transduced with these 
vectors to confirm expression (Fig. 13).  
 
 
 
 
 
 
 
 
Figure 13.  CPT1A-WT and CPT1A-Mu expression in primary hepatocytes. 
(A) HEK293 cells were infected with gAd.CPT1A-WT (CPT1A) or gAd.CPT1A-
Mu (CPT1Am), expressing wild type or mutant CPT1A, respectively. GFP, cells 
infected with a GFP-expressing virus. Neg., cells not infected with virus. Cells 
were harvested 30 h later. (B) Hepatocytes were infected with gAd.NEC (no 
expression cassette), gAd.CPT1A-WT or gAd.CPT1A-Mu at MOI 10 and 
harvested 48 h later.  
A 
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It has been shown that culturing primary hepatocytes under 
hyperinsulinemic conditions leads to increased expression of lipogenesis genes 
and decreased expression of enzymes implicated in FAO, such as CPT1A, as 
well as genes necessary for mitochondria biogenesis/function [156]. Thus, 
experiments were set up in primary hepatocytes cultured under hyperinsulinemic 
conditions to determine the effects of overexpressing wild type or malonyl-CoA 
insensitive CPT1A. Primary hepatocytes were infected with gAd.CPT1A-WT, 
gAd.CPT1A-Mu, or gAd.NEC (no expression cassette). Insulin resistance was 
observed in cells cultured with 5 nM insulin, relative to cells cultured with vehicle, 
based on decreased phosphorylation of AktSer473 and its downstream target 
molecule FoxO1Ser256 (Fig. 14). Although CPT1A expression was seen in primary 
hepatocytes treated with either CPT1A-WT or CPT1A-Mu under hyperinsulinemic 
conditions, no improvement in insulin signaling was observed, based on lack of a 
significant increase in AktSer473 and FoxO1Ser256 (Fig 14). 
 I then analyzed whether CPT1A overexpression can rescue an 
established insulin resistance. Hepatocytes were treated with high insulin prior to 
being infected with gAd.CPT1A-WT, gAd.CPT1A-Mu, or gAd.NEC. Similarly to 
the prevention study, both AktSer473 and Foxo1Ser256 levels were attenuated in 
cells treated with high insulin. However, CPT1A overexpression did not rescue 
insulin sensitivity (Fig 15). Thus, overexpressing CPT1A before the onset of 
insulin resistance or once insulin resistance is established, did not have the 
desired outcome of improving insulin signaling.  
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Figure 14.  Prevention study under hyperinsulinemic conditions. (A) Primary 
hepatocytes were infected with gAd.NEC, gAd.CPT1A-WT, or gAd.CPT1A-Mu 
for a total of 72 hours.  Cells were treated with 5 nM insulin for 48 hours, except 
for the insulin sensitive control group, which received vehicle. Insulin sensitivity 
was determined by culturing cells with vehicle or 20 nM insulin for 30 minutes. 
(B) Densitometry analysis of AktSer473 relative to total Akt, and of FoxO1Ser256 
relative to total FoxO1. The experiment was repeated using primary hepatocytes 
from an independent isolation, and similar results were obtained. *P<0.05 relative 
to insulin-sensitive cells. Statistical analysis done only on insulin treated group. 
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Figure 15.  Treatment study under hyperinsulinemic conditions. (A) Primary 
hepatocytes were treated with 5 nM insulin for 20 hours then infected with 
gAd.NEC, gAd.CPT1A-WT, or gAd.CPT1A-Mu for 4 hours. Cells were treated 
again with 5 nM insulin for 48 hours.  Insulin sensitive control group received 
vehicle. Insulin sensitivity assay was performed where the Basal group received 
vehicle and the Insulin group received 20 nM insulin for 30 minutes 52 hours post 
infection with virus. (B) Densitometry analysis of AktSer473 relative to total Akt, and 
of FoxO1Ser256 relative to total FoxO1. The experiment was repeated using 
primary hepatocytes from an independent isolation, and similar results were 
obtained. *P<0.05 relative to insulin-sensitive cells. Statistical analysis done only 
on insulin treated group. 
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CPT1A overexpression in primary hepatocytes does not rescue insulin resistance 
induced by hyperlipidemia 
 Studies have shown that exposing cells to large amounts of fatty acids, in 
particular palmitate, induces insulin resistance, impairing the insulin signaling 
pathway [157]. Thus, to induce insulin resistance, we used palmitate. Pilot 
studies were carried out in primary hepatocytes to determine the amount of 
palmitate (0.1-0.4 mM PA) conjugated to BSA that would induce insulin 
resistance in the absence of toxicity. A prevention or treatment set up were 
evaluated (data not shown). In addition to fatty acid concentration, several 
diluents, including ethanol, isopropanol, DMSO (dimethyl sulfoxide), and NaCl 
solution were tested. Ethanol, isopropanol and DMSO interfered with insulin 
signaling or caused toxicity (data not shown). Instead, dilution in NaCl solution 
did not induce toxicity, and this protocol was therefore used for all subsequent 
experiments (see Materials and methods for detailed description). Based on the 
results of these pilot experiments, the optimal amount of palmitate was 0.4 mM 
for the prevention study and 0.3 mM for the treatment study (Fig. 16).  
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Figure 16.  Palmitate induced insulin resistance in primary hepatocytes. 
Primary hepatocytes were treated with either 0.4 mM (prevention) or 0.3 mM 
(treatment) palmitate (PA) conjugated to BSA for 24 hours. BSA alone was used 
for control cells. For the prevention setup, cells were cultured in medium without 
fatty acid for 24 hours, then cultured with fatty acid for 24 hours. In the treatment 
setup, cells were cultured with fatty acid for 24 hours, then cultured in fresh 
medium without fatty acid for another 24 hours. Cells were then treated with 20 
nM insulin or vehicle for 30 minutes and then harvested at 48 hours. 
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Overexpressing CPT1A was expected to increase FAO and improve 
insulin signaling in primary hepatocytes. To evaluate if CPT1A overexpression 
could protect primary hepatocytes from developing insulin resistance, cells were 
treated with gAd.CPT1A-WT or gAd.CPT1A-Mu before adding PA (Fig. 17). As 
seen with the hyperinsulinemia conditions, palmitate induced a decrease in 
AktSer473 phosphorylation (Fig. 17). However, only a trend towards higher AktSer473 
levels were observed in CPT1A-treated samples relative to the NEC control 
group (Fig. 17), as the data were not statistically significant. In order to determine 
if the lack of rescue was due to limiting levels of carnitine, cells were cultured 
with 1 mM of L-carnitine, under the same conditions described in 'Prevention 
studies' (material and methods section). Again, no increase in AktSer473 levels 
was observed in cells treated with CPT1A relative to the NEC control group (data 
not shown). Thus, we conclude that CPT1A overexpression does not improve 
insulin signaling in primary hepatocytes.  
To study whether treating primary hepatocytes with CPT1A after insulin 
resistance had ensued, a similar experiment was set up, where primary 
hepatocytes were cultured with palmitate prior to transduction with gAd.CPT1A-
WT or gAd.CPT1A-Mu. Similar to what was observed in the prevention study, no 
improvement in insulin signaling was observed in the CPT1A overexpressing 
cells relative to NEC control cells, based on AktSer473 phosphorylation (Fig. 18). 
Taken together, CPT1A overexpression did not improve insulin sensitivity under 
hyperlipidemic conditions in primary hepatocytes. 
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Figure 17.  Prevention study under hyperlipidemia conditions. (A) Primary 
hepatocytes were infected with gAd.NEC, gAd.CPT1A-WT, or gAd.CPT1A-Mu 
for a total of 48 hours. Cells were treated with 0.4 mM palmitate for 6 hours, 
except for the insulin sensitive control group, which received BSA. Insulin 
sensitivity was determined by culturing cells with vehicle or 20 nM insulin for 30 
minutes 48 hours post-virus infection. (B) Densitometry analysis of AktSer473 
relative to total Akt. The experiment was repeated using primary hepatocytes 
from an independent isolation, and similar results were obtained. *P<0.05 relative 
to insulin-sensitive cells. Statistical analysis done only on insulin treated group. 
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Figure 18.  Treatment study under hyperlipidemia conditions. (A) Primary 
hepatocytes were treated with 0.3 mM palmitate for 20 hours, washed and 
cultured with gAd.NEC, gAd.CPT1A-WT, or gAd.CPT1A-Mu for 4 hours. Cells 
were treated again with 0.3 mM palmitate for an additional 24 hours. The insulin-
sensitive control group received BSA for the entire length of the experiment. 
Insulin sensitivity was determined by culturing cells with vehicle or 20 nM insulin 
for 30 minutes, 48 hours post-infection with adenovirus. (B) Densitometry 
analysis of AktSer473 relative to total Akt. The experiment was repeated using 
primary hepatocytes from an independent isolation, and similar results were 
obtained. *P<0.05 relative to insulin-sensitive cells. Statistical analysis done only 
on insulin treated group.  
B 
A 
74 
Discussion 
Results from in vitro and in vivo studies have highlighted the importance of 
CPT1A in the pathophysiology of NAFLD and insulin resistance. Overexpressing 
CPT1A in obese animals lowered hepatic lipid levels, and increased the rate of 
fatty acid oxidation by approximately 36%, compared with βgal-treated rats, 
suggesting this might be a viable option to treat hepatic steatosis and the 
underlying insulin resistance [158]. Likewise, Orellana-Gavaldà and colleagues 
demonstrated that high-fat diet fed mice overexpressing wild type CPT1A or a 
mutated form of CPT1A (malonyl-CoA insensitive) had decreased lipid 
accumulation and improved insulin sensitivity [151]. However, Monsénégo and 
colleagues showed that increasing FAO using a first generation adenovirus 
expressing malonyl-CoA-insensitive CPT1A, improved insulin signaling but failed 
to decrease accumulation of triglycerides in the liver of both high-fat diet fed and 
ob/ob mouse models, suggesting a disconnection between insulin resistance and 
hepatic steatosis.  
Here we demonstrated in primary hepatocytes that a similar prevention or 
treatment of insulin resistance approach does not lead to improvements in insulin 
sensitivity under hyperinsulinemia or hyperlipidemia conditions. This might be 
due the limitation of using primary cells, which only allow carrying out 
experiments for a few days, as cells become quickly senescent. Thus, it is 
possible that longer expression of CPT1A is needed to overcome the effects of 
high insulin or high fatty acids on insulin signaling. It is also possible that CPT1A 
treatment reduced the amount of fatty acid buildup without improving insulin 
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sensitivity, and future work is needed to address this possibility. In addition, there 
could be other factors controlling insulin signaling in primary hepatocytes and 
CPT1A overexpression was not enough to improve insulin sensitivity on its own. 
Even though CPT1A overexpression did not have a positive outcome on 
insulin sensitivity, the system can be used in future studies to address the impact 
of exposure to hyperinsulinemia or to high glucose/high fatty acids on CPT1A 
activity, as well as on mitochondrial dysfunction. Furthermore, studies looking at 
genes involved in mitochondrial biogenesis, FAO, gluconeogenesis, and 
lipogenesis can also be evaluated. Impaired mitochondrial function plays a 
pivotal role in the development of hepatic steatosis [159, 160]. Recent findings 
suggest that mitochondrial dysfunction leads to impaired FAO, raising the idea 
that NAFLD is actually a result of defective mitochondria, and implying that 
decreased FAO is merely a consequence [161]. Some of the aspects leading to 
mitochondria dysfunction could be studied under controlled conditions in primary 
hepatocytes. Finally, in vitro studies to measure rates of FAO can be developed 
based on oxygen consumption and CO2 production rates using a Seahorse XF 
analyzer (Agilent Technologies, MA).   
In conclusion, I was able to induce insulin resistance in primary 
hepatocytes using two different approaches and under two different conditions. In 
addition, I showed that insulin resistance can occur separately regardless of fatty 
acid induction or chronic insulin induction and that overexpression of CPT1A 
alone cannot improve this phenotype. 
76 
Chapter 3: Silencing Sterol Regulatory Element Binding Protein-1  
(SREBP-1) reduces insulin signaling in mouse liver 
 
Introduction 
 Sterol Regulatory Element Binding Protein-1 (SREBP-1) is a conserved 
transcription factor of the basic helix-loop-helix leucine zipper family (bHLH-Zip) 
that primarily regulates expression of genes of fatty acid metabolism.  SREBPs 
are bound to the endoplasmic reticulum membrane. In response to specific 
signals, SREBPs transition to the Golgi, where they are cleaved, releasing the 
mature form, which subsequently translocates to the nucleus [43]. SREBP-1a 
and SREBP-1c are isoforms of the same gene, and their role as transcription 
regulators of enzymes in the glycolysis and de novo lipogenesis (DNL) pathways, 
is well established [43].  Additional functions are emerging from recent studies, 
which have revealed that SREBP-1 regulates a complex gene network to 
coordinate metabolic responses needed for cell survival and growth, including 
fatty acid metabolism [43]; glycogen synthesis and gluconeogenesis [147]; 
phagocytosis and membrane biosynthesis[162]; pro-inflammatory response 
[163]; and cell proliferation [75]. In addition, SREBP-1 is implicated in the control 
of the insulin signaling pathway through feedback regulation of key molecules 
like IRS2 and PIK3R3 [74, 76].  
 Cell growth is linked to the availability of nutrients and energy to generate 
new lipids, cell membranes, and nucleic acids. During periods of fasting, low 
energy and nutrient availability are sensed by a complex network of molecules, 
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shutting down biosynthetic programs that consume energy. The kinase target of 
rapamycin (TOR) is a highly conserved protein from yeast to mammals, and 
plays a key role at orchestrating fundamental aspects of metabolism, cellular 
growth, proliferation and survival. Two complexes exist, TORC1 and TORC2, 
with distinct functions. In mammals, mTORC1 regulates ribosome biogenesis 
and protein synthesis [164], and mTORC2 regulates actin cytoskeleton 
organization [165, 166]. Unique protein subunits participate in the specific 
functions of each complex. The major partner of mTORC1 is regulatory-
associated protein of mTOR (Raptor) [167, 168], while mTORC2 associates with 
rapamycin-insensitive companion of mTOR (Rictor) [166]. The 70 kDa ribosomal 
protein S6 kinase (RPS6KB1 or S6K1) is a serine/threonine kinase that becomes 
activated in response to nutrients and growth factors. S6K1 lies downstream of 
the mTORC1 complex, and its activity is enhanced by insulin signaling [104]. The 
major biological effect resulting from phosphorylation and activation of S6K, is 
protein synthesis. S6K1 also regulates the insulin signaling pathway by 
phosphorylating serine residues in IRS1 [169], thereby impairing IRS1 mobility 
and contact with the insulin receptor for tyrosine phosphorylation [170]. In fact, 
high nutrient intake has been associated with overactivation of S6K1 in the liver, 
with subsequent inhibition of insulin signaling [169, 171]. Insulin-induced SREBP-
1 transcription activation is mediated by mTORC1 [172-174], and several lines of 
evidence have shown that mTORC1 is also implicated in the processing from 
precursor to the mature form [174-176]. Nevertheless, there are conflicting 
results on whether S6K1 mediates mTORC1 effects on the transcriptional 
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activation of SREBP-1 [172, 177]. In contrast, there is substantial evidence that 
S6K1 promotes SREBP-1 processing [175].  
 Given the role of mTORC1 in promoting protein and lipid biosynthesis 
needed to support cell growth and survival, and the role of SREBP-1 in 
sustaining anabolic processes, we questioned whether SREBP-1 regulates the 
mTOR pathway in a regulatory feedback mechanism. Our data indicates that 
silencing SREBP-1 has important consequences for S6K1 expression and 
mTORC1/2 function. In addition, lack of SREBP-1 impacts insulin signaling, 
underscoring the importance of this transcription factor as coordinator of anabolic 
processes in response to nutrient availability.  
 
Materials and methods 
Animals 
 All animal studies were in accordance with the National Institutes of Health 
guidelines and were approved by the Indiana University School of Medicine 
Institutional Animal Care and Use Committee. Male eight-week old C57BLKS/J 
and db/db mice were obtained from The Jackson Laboratory (Bar Harbor, ME), 
and allowed to acclimate for at least a week before experimentation. A standard 
12 h light/12 h dark cycle (7 AM/7 PM) was maintained throughout the 
experiments. Mice were maintained in a BSL2-certified room and were fed rodent 
chow ad libitum and allowed free access of water. C57BLKS/J mice were given 
1x1011 viral particles (vp) by tail vein injection, and euthanized 7 days after 
adenovirus vector administration under ad libitum fed conditions, 24-h fasted or 
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24-h fasted followed by a 4-h re-feeding period. db/db mice were given 1x1011 
vp, and euthanized 3 weeks later under fed or 24-h fasted conditions. Tissues 
were collected and snap frozen in liquid nitrogen or fixed in 10% buffered 
formalin for histology analysis. Male C57BL/6J mice (24 to 30g) were used for 
isolation of primary hepatocytes. 
 
Helper-dependent adenoviral vector production 
 The development of helper-dependent adenoviral vectors to target 
SREBP-1 or expressing a scrambled sequenced has been previously described 
[178]. Vectors were stored at -80°C in 10 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 
150 mM NaCl, 10% glycerol. Total particle counts were determined 
spectrophotometrically, as described [178]. 
 
Primary hepatocyte isolation and cell culture 
 Primary hepatocytes were isolated from C57BL/6J mice using a two-step 
collagenase procedure followed by Percoll gradient centrifugation, to separate 
hepatocytes from non-parenchymal cells, as previously described [98]. Cell 
viability was assessed by trypan blue staining exclusion (>80% viability). Cells 
were seeded at a density of 4-6x105 cells per well or 35-mm dish in DMEM 
supplemented with 10% (v/v) fetal bovine serum (FBS), 1% (v/v) 
penicillin/streptomycin (P/S), 3 nM insulin and 1 nM dexamethasone. Cells were 
incubated at 37°C, 5% CO2 in a humidified incubator and allowed to attach for 4 
hours. Media was then replaced with fresh media.  
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 For experiments addressing the response to insulin, primary hepatocytes 
were isolated and infected with gAd.shSCR or gAd.shSREBP-1 adenovirus at 
MOI 4. Media was changed the next day. Cells were incubated at 37°C for 71 
hours and then washed twice with 1xPBS. Cells were cultured in DMEM 
supplemented with 5 mM glucose and 1% P/S for 1 hour. Cells were then 
incubated with 20 nM insulin for 5, 15, 30, 45, and 60 minutes. A subset of wells 
was incubated with 20 nM insulin for 15 minutes, and then insulin was removed. 
Cells were harvested after 5, 15, 30, and 45 minutes.  
 Hepa1c1c7 cells (American Type Culture Collection, Manassas, VA) were 
cultured in MEM-α supplemented with 10% FBS and 1% (v/v) P/S. Cells were 
seeded at 4x105 cells per well. 
 
Cell transfection 
 Mouse primary hepatocytes, mouse hepatoma cell line (Hepa1c1c7) were 
transfected with 1-2 µg plasmids, or 1.5 µg mouse SREBP1 siRNA or non-
targeting control siRNA (Dharmacon, Lafayette, CO). Transfection was 
performed with Metafectene-Pro (Biontex, Munich, Germany), as described [98]. 
After overnight incubation, media was replaced with fresh media. Cells were 
harvest between 48 and 72 hours. 
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qRT-PCR analysis 
 Total RNA was isolated from primary hepatocytes (Qiagen). qRT-PCR 
was carried out  in an ABI 7500 instrument (Applied Biosystems, Foster City, CA) 
using the SYBR Green Qiagen One-Step reverse transcription-PCR kit (Qiagen, 
Valencia, CA) and the following primer pairs: RPS6KB1,  5’-
CTCAGTGGAGGAGAACTATTTA-3’ and 5’-CCAGGCTCCACCAGTCCAC-3’; β-
actin,  5’-CTACAATGAGCTGCGTGTGGC-3’ and 5’-
ATGGCTGGGGTGTTGAAGGTC-3’. Primer pairs were designed to bind different 
exons of the gene and to generate fragments of approximately 200 bp. The 
reaction was first confirmed to yield a single band of the expected size by 
agarose gel electrophoresis, and lack of amplification in wells containing sample 
without reverse transcriptase. The relative quantification of the gene was 
normalized with β-actin. 
 
Western blotting 
 Primary hepatocytes and hepatocellular carcinoma cell lines were lysed in 
RIPA buffer (Thermo Scientific, Rockford, IL) containing protease and 
phosphatase inhibitors (Roche, Indianapolis, IN). Protein concentration was 
determined using the BCA kit from Pierce (Rockford, IL). Proteins (7-30 µg) were 
separated in 10% or 4-20% Tris-HCl SDS PAGE Criterion gel (Bio-Rad, 
Hercules, CA) and transferred to 0.2-mm PVDF membrane (Bio-Rad). 
Membranes were blocked with 5% BSA-TBST or 5% dry milk-TBST for 1-2 h and 
incubated with the following antibodies: AktSer473, AktThr308 and Akt (Pan); 
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Foxo1Ser256 and Foxo1; GSK3αSer21 and GSK3α; Irs1Ser302 and IRS1; mTORSer2448 
and mTOR; RictorThr1135 and Rictor, Raptor, p70 S6 kinase (S6K), Acetyl-Coa 
Carboxylase (ACC1/2) (Cell Signaling, Boston, MA), α-tubulin; SREBP1 (Thermo 
Scientific, Rockford, IL), β-actin (Santa Cruz Biotechnology, Dallas, TX), 
Cyclophillin-40, (Abcam, Cambridge, MA),  IRS2 (EMD Millipore, Billerica, 
Massachusetts), and IRS1Tyr612 (Invitrogen, Life Technologies, Grand Island, 
NY). HRP-conjugated secondary antibody was added and incubated at room 
temperature for 1 hour. Blots were developed with Pierce ECL kit (Thermo 
Scientific) and exposed to enhanced chemiluminescence (ECL) film (GE 
Healthcare, Piscataway, NJ). 
 
Luciferase constructs and assay 
 pGL4.10-S6K-WT construct was generated by cloning a portion of the 
S6K promoter followed by an internal ribosomal entry site (IRES) upstream from 
the firefly luciferase gene in plasmid pGL4.10 (luc2) (Promega, Madison, WI). 
IRES was amplified from plasmid pT7CFE1-NHis (Fisher Thermo Scientific, 
Rockford, IL) using the following oligonucleotides: 5’-
TATGCAGATATCGGTTATTTTCCACCATATTG-3’ and 5’-
AATCAGAGATCTTTTCAAAGGAAAACCACGTC-3’, and inserted into the 
EcoRV-BglII sites using Quick ligation kit (New England Biolabs, Ipswich, MA). 
The S6K1 promoter plus part of the first intron containing two SRE binding sites 
(positions -589 to +709 from the transcription start site) was amplified from 
mouse genomic DNA using the following oligonucleotides: 5’-
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TATGCAGCTAGCAAAGGAGCAGAGGCTTGTGAA-3’ and 5’-
AATCAGCTCGCGTCCGCATCTCACCTGCACTAA-3’. The fragment was 
inserted into the NheI and XhoI sites in pGL4.10(luc2). Mutations of both SRE 
sites were made using site directed mutagenesis (Agilent Technologies, Quick 
Change II Site-directed Mutagenesis Kit, Santa Clara, CA) and the following 
primers: 5’-CTGAGGATGAGCTGGAGGATTTTGTGAGGCCCGGGGTCCC-3’ 
and 5’-GGGACCCCGGGCCTCACAAAATCCTCCAGCTCATCCTCAG-3’ for the 
first SRE site and 5’-
CTTGAGTGCGGCCCGGGTGAAAAAAGCGTGTGCTGGGGGTGG-3’ and 5’-
CCACCCCCAGCACACGCTTTTTTCACCCGGGCCGCACTCAAG-3’ for the 
second site to generate pGL4.10-S6K-Mut1 and pGL4.10-S6K-Mut2 constructs. 
All clones were sequenced prior to using them in luciferase assays. Low passage 
293 cells (Microbix Biosystems, Inc., Ontario, Canada) were cultured in MEM-α 
supplemented with 10% FBS and 1% P/S. Cells were co-transfected with 225 ng 
of SREBP-1a, SREBP-1c, or GFP plasmids; 675 ng of pGL4.10-S6K-Wt, 
pGL4.10-S6K-Mut1, or pGL4.10-S6K-Mut2 plasmids; and 150 ng of pRES-EIFα-
β-gal plasmid. Cells were incubated at 37°C in a 5% CO2 incubator. Cells were 
harvested 18 hours later and analyzed for luciferase activity using the 
Luciferase® reporter assay system (Promega) and a luminometer (Centro LB 
960 microplate luminometer, Berthold Technologies). β-galactosidase enzyme 
assay system (Promega) was used to normalize firefly luciferase activity. 
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Statistical analysis 
Numerical values represent mean ± SD. P values were calculated using unpaired 
two-tailed Student’s t-tests. A P value of less than 0.05 was considered 
statistically significant. 
 
Results  
SREBP-1 regulates S6K1 
 Data generated from the ENCODE project (http://genome.ucsc.edu/) 
indicates that the promoter of the S6K1 gene is protected from DNAse digestion, 
and the protection extends into the first intron of the gene, suggesting the 
presence of regulatory proteins in this area. Furthermore, genome-wide ChIP-
seq studies have shown that SREBP-1 binds to the S6K1 gene in the human 
hepatoma cell line HepG2 [179] and in mouse liver [78]. Using TRANSFAC 
(Waltham, MA) we identified two putative SRE-binding sites in the first intron of 
the S6K1 gene. Furthermore, this area is highly conserved between mouse and 
human (Fig. 19A). Both sites are in reverse orientation. To test the functionality of 
these sites, luciferase reporter constructs were generated containing a fragment 
from -589 to +709 of the transcription start site (TSS), with or without mutated 
SRE binding sites (Fig. 19A). HEK293 cells were co-transfected with these 
plasmids and a plasmid expressing the nuclear form of SREBP-1a or SREBP-1c. 
Luciferase expression was significantly reduced in cells with the mutated binding 
sites relative to those with the wild-type sequence (Fig. 19B).  
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Figure 19. SREBP-1 binds to SRE motifs present in the first intron of the 
S6K1 promoter. (A) Schematic representation of the portion of the S6K1 
promoter cloned with relevant SRE binding sites.  (B) HEK293 cells were co-
transfected with pGL4.10-S6K-WT(WT),  pGL4.10-S6K-Mut1 (M1) or pGL4.10-
S6K-Mut2 (M2) constructs and SREBP-1a, SREBP-1c, or GFP plasmids. A total 
of 1 ug of DNA was used. Eighteen hours later, cells were harvested and 
luciferase was analyzed. *p<0.05; n=3. Abbreviations: UT, untransfected; Sp1, 
Specificity protein 1; SRE, Sterol regulatory element motif. 
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 To validate these results, primary hepatocytes were depleted of SREBP-1 
via adenovirus-mediated shRNA expression or transfection using siRNA. As 
shown in Fig. 20A and 20B, levels of S6K1 protein and mRNA were significantly 
lower in primary hepatocytes treated with shSREBP1. Likewise, siRNA against 
SREBP-1 induced the same effects on S6K1 protein (Fig. 20C). Furthermore, the 
reduction in S6K1 expression was rescued by overexpression of the nuclear form 
of human SREBP-1c, which is not targeted by the shRNA against the mouse 
transcript (Fig. 20D). Similar data were observed using shRNA or siRNA in 
mouse hepatoma Hepa1c1c cells (data not shown). Overall, these data suggest 
that S6K1 is a direct target of SREBP-1.  
 
Positive feedback between SREBP-1 and mTORC1  
 The results in primary hepatocytes suggested that SREBP-1 is needed for 
regulation of S6K1. We then analyzed the implications of silencing SREBP-1 in 
vivo, on mTOR and the insulin signaling pathway. Depleting SREBP-1 in normal 
mice resulted in a moderate decrease in S6K1, under fed conditions. It has been 
previously described that silencing SREBP-1 in hepatocellular carcinoma cell 
lines leads to a significant decrease in AktSer473 phosphorylation, while 
overexpression of SREBP-1 results in increased phosphorylation [115]. Thus, we 
questioned whether this would be the case in normal liver. Interestingly, a 
moderate decrease in IRS1Y612, AktSer473 and GSK3αSer21 phosphorylation was 
observed, under fast and re-fed conditions, suggesting lower insulin sensitivity 
(Fig. 21).   
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Figure 20. Silencing SREBP-1 downregulates S6K1 expression. (A) Primary 
hepatocytes were infected with gAd.shSCR (shSCR) or gAd.shSREBP-1 (SRP1) 
at MOI 3 for 72 hours, and protein lysates were generated for WB analysis (B) 
Primary hepatocytes were infected with gAd.shSCR or gAd.shSREBP-1 at MOI 3 
for 72 hours. RNA lysates were generated and qRT-PCR for S6K1 was 
performed. (C) Primary hepatocytes were transfected with 1.5 ug non-targeting 
control siRNA (siNC) or siSREBP-1 (siSRP1). Cells were harvested 72 hours 
later, and protein lysates were generated. (D) Primary hepatocytes were infected 
with gAd.shSCR or gAd.shSREBP-1 at MOI 3, 4 hours post plating. Medium was 
changed the next day and cells were transfected with SREBP-1c or GFP 
plasmids (1.5 ug). Cells were harvested 72 hours post-infection. 
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Figure 21. Silencing SREBP-1 downregulates S6K1 expression in normal 
mice, and reduces insulin signaling. Groups of five C57BKS mice were given 
1x1011 vp gAd.shSCR or gAd.shSREBP1 and euthanized one week later under 
fed, 24-hour fasted, and 24-hour fasted followed by 5 hour re-feeding conditions. 
Protein lysates were generated from liver samples. Abbreviations: shSCR, 
gAd.shSCR; SRP1, gAd.shSREBP-1.  
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 Although the mechanisms by which the decrease occurs are unknown, it 
is possible that SREBP-1 silencing triggers an attenuated response to insulin 
signaling due to changes in the composition of lipid rafts [180, 181]. The PI3K-
Akt-mTORC1 axis is important to determine appropriate levels of fatty acids and 
cholesterol and for the integrity of lipid rafts [182].  
 SREBP-1 activity is higher in diet-induced obesity, db/db [183] and ob/ob 
mice [184], underscoring the role of this transcription factor in the etiology of 
hepatic insulin resistance. Similarly, increased S6K1 activity has also been 
reported in diet-induced obesity and insulin resistance [171]. Remarkably, 
silencing SREBP-1 in db/db mice resulted in significantly reduced S6K1 protein 
levels under fed and fasted conditions (Fig. 22A and 23), suggesting SREBP-1 is 
needed to maintain the high levels of S6K1 in this animal model. Depleting 
SREBP-1 did not induce changes in mTOR levels, although its activity was lower 
than in control animals, based on phosphorylation at Ser2448 [185]. Despite no 
alterations in total levels of mTOR, a moderate increase in Rictor and a decrease 
in Raptor were also observed (Fig. 22A), suggesting that mTORC1 activity was 
reduced while mTORC2 was more active. Furthermore, AMPK, a known 
mTORC1 inhibitor, was found activated under fed conditions (Fig. 22C). 
Altogether, these data suggest that silencing SREBP-1 in db/db mice leads to an 
increase in mTORC2 activity while decreasing mTORC1 activity. 
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Figure 22. Silencing SREBP-1 downregulates S6K1 expression in db/db 
mice. Groups of eight db/db mice were given 1x1011 vp gAd.shSCR or 
gAd.shSREBP1 through the tail vein, and euthanized three weeks later under fed 
(ad libitum) or 24-hour fasted conditions. Protein lysates were generated from 
liver samples. (A) Effects of silencing SREBP-1 on molecules in the mTOR 
pathway. (B) Effect of silencing SREBP-1 on molecules in the insulin signaling 
pathway. (C) Under fed conditions, silencing SREBP-1 activates AMPK, a 
molecule involved in cellular energy homeostasis. 
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 Silencing SREBP-1 in db/db animals resulted in increased AktS473 
phosphorylation under fed conditions (Fig. 22B). Furthermore, in an insulin 
sensitivity test, fasting mice for 5 hours was not sufficient to reduce AktS473 to 
basal levels (Fig. 23), suggesting a defect in the inhibition of insulin signaling. 
Insulin administration did not further increase phosphorylation of AktS473. 
mTORC1 negatively regulates the response to insulin and insulin-like growth 
factor 1 by inhibiting mTORC2, and this effect is mediated by S6K1 [39, 186]. By 
phosphorylating Rictor, S6K1 inhibits mTORC2, preventing phosphorylation of 
Akt at Ser473 [39, 186]. Thus, we questioned whether the decrease in S6K1 
would be associated with a decrease in phosphorylation of RictorThr1135 and as a 
result, AktSer473 phosphorylation would be increased. As shown in Fig. 22 and 23, 
RictorThr1135 was lower under fasting conditions. Thus, inhibiting SREBP-1 
reduces S6K1, which possibly fails to inhibit mTORC2, resulting in enhanced 
AktSer473 phosphorylation. No significant differences on insulin signaling were 
observed in adipose tissue or skeletal muscle, as expected (Fig. 24). 
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Figure 23. Insulin sensitivity analysis in db/db mice (liver). Groups of seven 
db/db mice were given 1x1011 vp gAd.shSCR or gAd.shSREBP1 through the tail 
vein. Three weeks later, mice were fasted for 5 hours and given vehicle or insulin 
via portal vein. Mice were euthanized 5 minutes later. Liver was flash frozen and 
protein lysates were generated. The densitometry analysis of IRS1Y612, AktSer473 
and AktThr308 relative to total Akt levels, is shown on the right. * p<0.05 between 
shSCR and shSREBP groups; # p<0.05 between vehicle and insulin-treated. 
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Figure 24. Insulin sensitivity analysis in db/db mice (skeletal muscle and 
adipose tissue). Groups of seven db/db mice were given 1x1011 vp gAd.shSCR 
or gAd.shSREBP1 through the tail vein. Three weeks later, mice were fasted for 
5 hours and given vehicle or insulin via portal vein. Mice were euthanized 5 
minutes later. Skeletal muscle and adipose tissue was flash-frozen and protein 
lysates were generated. 
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Insulin signaling kinetics  
 The increase in AktS473 under hyperinsulinemic conditions (db/db mice), 
suggested a defect in inhibition of insulin signaling. To study this is more detail, 
we analyzed the response of hepatocytes to insulin in a time course experiment. 
Primary hepatocytes were cultured with 20 nM insulin and harvested 5, 15, 30, 
46 and 60 minutes later. In SREBP-1 depleted cells, S6K1 and S6 
phosphorylation were significantly lower, as expected from the lower levels of 
S6K1 (Fig. 25). However, AktSer473 phosphorylation was significantly higher at all 
time points. We then analyzed whether the response to insulin was shutdown 
with a similar kinetics. Primary hepatocytes were cultured with 20 nM insulin for 
15 minutes; insulin was removed and cells were harvested at several time points. 
Although insulin signaling was shutdown with a similar kinetics, the signal 
remained higher in cells depleted of SREBP-1 relative to control cells (Fig. 25). 
These data suggest that insulin signaling may not be appropriately inhibited in 
the absence of SREBP-1, and lack of inhibition leads to increased AktSer473 
phosphorylation.  
 
  
95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Insulin kinetics in primary hepatocytes. (A) Primary hepatocytes 
were transduced with gAd.shSCR or gAd.shSREBP-1 at MOI 3. Seventy-two 
hours post infection, cells were fasted for 1 hour and cultured with 20 nM insulin. 
Cells were harvested at the time points shown on the top. (B) Primary 
hepatocytes were transduced with gAd.shSCR or gAd.shSREBP-1 at MOI 3.  
Seventy-two hours post infection, cells were fasted for 1 hour and cultured with 
20 nM insulin for 15 minutes. After removal of insulin, cells were harvested at the 
time points shown on the top. 
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Discussion 
 In the present study, we have shown that a positive feedback mechanism 
exists between SREBP-1 and mTORC1 through direct regulation of S6K1. The 
SREBP-1 binding sites are located in the first intron of the gene in a reverse 
orientation, in an area highly conserved between mouse and human, and this 
enhancer is likely to contribute to the overall level of expression of the gene. The 
SRE sites are located adjacent to SP1 binding sites, which are frequently found 
in promoters regulated by SREBP-1. There is a precedent for SREBP-1 binding 
to an enhancer located in an intron [77]. Caspase-2 has been shown to regulate 
lipid synthesis and its transcription is activated by SREBPs [187]. SREBP-1c, in 
particular, binds to an E-box in an enhancer located in the first intron [77]. Unlike 
the S6K1 gene, this site is not conserved across species, and is only present in 
human cells [77]. Thus, S6K1 exemplifies a unique case of an enhancer located 
in a highly conserved intronic region. 
 Functionally, the activation of S6K1 denotes a coordinated action between 
SREBP-1 and mTORC1 function. Several studies have demonstrated that 
mTORC1 mediates the response of insulin on activation of SREBP-1 and 
lipogenesis, as blocking mTORC1 activity with rapamycin inhibits SREBP-1 
expression [172, 176, 177]. In addition, both mTORC1 and SREBP-1 activity are 
enhanced in liver of animal models of obesity and type 2 diabetes [171, 184, 
188]. Furthermore, mice with liver-specific Raptor deficiency are protected 
against non-alcoholic fatty liver disease (NAFLD) [173]. However, it remains 
unclear whether S6K1 plays a role as regulator of SREBP-1. On one side, 
97 
inhibiting S6K activity with LYS6K2 does not affect the induction of SREBP-1 
expression in response to insulin, suggesting another molecule downstream from 
mTORC1 induces this effect [172]. On the other, knocking down S6K1 in 
immortalized hepatocytes or in mouse liver, severely blunts SREBP-1 expression 
and triglyceride accumulation [177]. Regardless of whether S6K1 or a different 
mTORC1 downstream effector is implicated in the regulation of SREBP-1, our 
data suggest that SREBP-1 regulates S6K1 in a positive feedback mechanism to 
enhance protein synthesis. Thus, SREBP-1 facilitates multiple anabolic 
processes relevant to the fed state, including lipogenesis, protein synthesis, and 
glycogen synthesis. 
 The mTOR pathway functions as the hub for sensing nutrient abundance 
and changes in energy supplies [189]. Protein kinase B (Akt) is a critical signaling 
molecule that regulates a variety of cellular functions, including metabolism, 
survival, growth and proliferation [190]. The Akt/mTORC1 axis is deregulated in 
many cancers, and it has emerged as a critical regulatory point in the control of 
cell growth and cellular proliferation. Indeed, Akt is hyperactivated in many 
cancers [191-193], and mTORC1 has been used as a target to treat a variety of 
tumors [194, 195]. Enhanced mTORC1 activity in these tumors is associated with 
increased expression of SREBP-1, and emerging evidence is showing that 
lipogenesis is strongly associated with poor survival [115, 196]. Hence, SREBP-1 
is receiving a lot of attention as a potential oncogene, as multiple studies have 
emphasized the association between its activity and cell growth and proliferation 
[196]. In fact, overexpression of SREBP-1 in HCC cell lines with low levels of 
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SREBP-1, accelerated their growth and reduced apoptosis. Remarkably, this was 
accompanied by increased levels of phosphorylated AktSer473 [115]. Conversely, 
in HCC cell lines expressing high SREBP-1 levels, knocking down SREBP-1 or 
any of its downstream effectors, reduced AktSer473 activity [115]. These data 
emphasize the connection between Akt/mTORC1/SREBP-1, to coordinate 
lipogenesis and cellular growth in liver. In agreement with these data, our results 
show that in normal mice, SREBP-1 deficiency is associated with lower IRS1Y612 
and AktSer473, Thr308 (fasting conditions), concurring with previous reports in liver 
cell lines [115]. Although the mechanism leading to this reduction is yet to be 
elucidated, it is possible that is attributable to alterations in the composition of 
lipid rafts [181]. 
 Previous studies have shown that mTORC1 is a negative regulator of 
mTORC2, and this effect is mediated by S6K1 [39, 186]. Thus, S6K1 negatively 
regulates the insulin signaling pathway by phosphorylating Rictor, thereby 
disrupting mTORC2 activity and precluding phosphorylation of AktSer473 [39, 186]. 
Our data indicates that in vivo, this negative regulation may be important when 
insulin levels are high, as occurs in db/db animals. In fact, the decrease in S6K1 
resulting from silencing SREBP-1 in db/db mice, was associated with significantly 
higher AktSer473 under fed conditions. In an insulin sensitivity assay, fasting mice 
for 5 hours did not reduce AktSer473 to basal levels. Fasting for 24 hours was 
needed to reduce AktSer473 to basal levels, as seen in control db/db mice. This is 
consistent with the notion that insulin signaling is not appropriately shutdown, as 
IRS1Y612 remained lower relative to control animals, discarding the possibility of 
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increased insulin sensitivity. The observation that RictorThr1135 phosphorylation 
was lower in db/db mice lacking SREBP-1, suggests a possible mechanism for 
lack of inhibition of insulin signaling. Further studies are needed to investigate the 
detailed mechanisms through which this inhibitory activity takes place. 
 In conclusion, our data indicates that SREBP-1 binds to an enhancer in 
the first intron of the S6K1 gene, and is likely to contribute to the overall 
expression levels of this gene. In vivo, silencing SREBP-1 has significant 
implications for insulin signaling. In normal mice, reduced AktSer473 is observed, in 
particular under fasting conditions, and no effects are seen during the fed state. 
However, under hyperinsulinemic conditions, SREBP-1 depletion leads to 
significant changes in AktSer473, and our data suggest that this is the result of lack 
of inhibition rather than enhanced sensitivity to insulin. Our data provides 
evidence that SREBP-1 coordinates multiple metabolic pathways by not only 
activating lipogenesis, but also promoting protein synthesis, and thus, it 
coordinates multiple aspects of the anabolic response in response to nutrient 
abundance.  
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
The non-alcoholic fatty liver disease (NAFLD) epidemic has been 
estimated to affect 75-100 million people in the United States, and continues to 
be the leading cause of liver diseases in the world [107]. In addition, non-
alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), affecting 
5% and 0.006% of the US general population, respectively, are also becoming a 
concern [106, 107]. The link between the mTOR pathway and insulin signaling in 
relation to the pathophysiology of the aforementioned diseases has been broadly 
studied. The transcription factor SREBP-1, a downstream effector of insulin 
signaling through mTORC1, is up-regulated in these metabolic diseases, 
activating the de novo lipogenesis and glycolysis pathways. However, its role 
outside of being a contributing factor to hepatic lipid accumulation and insulin 
resistance, was not well known. Therefore we sought to explore its role in other 
pathways such as carbohydrate metabolism, insulin signaling, and mTOR. 
We proposed to silence SREBP-1 in db/db mice, a diabetes mouse model, 
which exhibits hyperinsulinemia, hyperglycemia, and insulin resistance, as well 
as β-cell dysfunction [197], to examine the impact on carbohydrate metabolism. 
In normal animals, SREBP-1 depletion increased Pck1 and reduced glycogen 
deposition under fed conditions, providing evidence that SREBP-1 is necessary 
to regulate carbohydrate metabolism during the fed state. As expected, knocking 
SREBP-1 down in db/db mice resulted in a significant reduction in de novo 
lipogenesis and triglyceride accumulation. However, mice remained 
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hyperglycemic, and no improvements in glucose or insulin tolerance were seen.  
As observed in normal mice, silencing SREBP-1 in db/db animals resulted in up-
regulation of gluconeogenesis gene expression as well as decreased glycolysis 
and glycogen synthesis gene expression. Furthermore, glycogen synthase 
activity and glycogen accumulation were significantly reduced, suggesting 
SREBP-1 is needed under fed conditions to promote glycogen synthesis. Thus, 
SREBP-1 depletion leads to significant changes in carbohydrate metabolism and 
suggests that SREBP-1 plays additional roles in metabolism besides controlling 
lipogenesis. Future studies will be needed to further evaluate whether the 
alterations in mRNA/protein levels observed lead to increased hepatic glucose 
output, using pyruvate tolerance tests or metabolic tracers in vitro and/or in vivo. 
Another outcome of these studies was the observation that FAO did not 
increase upon silencing SREBP-1, as we had predicted. This lead to the notion 
that perhaps in this animal model mitochondria are not healthy to sustain 
additional FAO, or that CPT1A activity may be limiting. Individuals with obesity 
and type 2 diabetes exhibit hepatic lipid accumulation, which contributes to the 
induction of insulin resistance and impaired insulin signaling [24]. As mentioned 
previously, chronic exposure to insulin enhances the accumulation of lipids in the 
liver by stimulating de novo lipogenesis, thus inhibiting fatty acid oxidation (FAO). 
This inhibition is mediated by malonyl-CoA, an allosteric inhibitor of carnitine 
palmitoyltransferase 1A (CPT1A) [156]. Since CPT1A is a rate-limiting enzyme in 
the oxidation of fatty acids in mitochondria, increasing its activity has been 
devised as a therapeutic approach to decrease hepatic steatosis and improve 
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insulin sensitivity. In fact, increasing the levels of CPT1A has resulted in 
attenuated insulin resistance and intracellular lipid regulation in several studies 
[150-152, 198]. To determine if insulin resistance could be improved by 
overexpression of CPT1A in a controlled environment, we used adenoviral 
vectors expressing wild type or malonyl-CoA resistant CPT1A (gAd.CPT1A-WT, 
or gAd.CPT1A-Mu) in primary hepatocytes. Hepatocytes were treated under 
either hyperinsulinemic or hyperlipidemic environments, and the effects of over-
expressing CPT1A as a mechanism to reduce steatosis and improve insulin 
sensitivity were evaluated. Our results showed that overexpressing CPT1A did 
not prevent the insulin resistance due to hyperinsulinemia or hyperlipidemia, 
regardless of when insulin resistance was established, i.e. before or after 
overexpression of CPT1A. These data indicate that the effects observed in vivo 
may require expression of CPT1A for longer time than what is possible in primary 
cultures. Despite the lack of efficacy at improving insulin resistance, these 
studies have enabled us to establish a system to induce insulin resistance using 
lipids and/or insulin for in vitro experiments in primary hepatocytes. This system 
allows more control of the cellular environment to perform studies that 
complement the data generated from in vivo experiments, and we used it for 
studying insulin signaling in relation to SREBP-1 deficiency.  
Studies using genome-wide chromatin immunoprecipitation followed by 
sequencing (ChIP-seq) have shown that SREBP-1 binds to the promoter of S6K1 
in mouse liver as well as in human hepatocellular carcinoma HepG2 cells [78, 
179]. mTORC1 regulates SREBP-1 and S6K [101]. Here we have provided 
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evidence that SREBP-1 may regulate S6K1, in a positive feedback loop. We 
demonstrated that in db/db mice, depletion of SREBP-1 resulted in a significant 
decrease in S6K under fed and fasted conditions. In addition, protein and mRNA 
levels were decreased in primary hepatocytes treated with shSREBP-1 
adenovirus compared to the control group. Thus, decreasing SREBP-1 had a 
significant effect on S6K expression. Furthermore, the drop of S6K was rescued 
by expression of constitutively active SREBP-1c. In addition, using luciferase 
reporter assays we demonstrated that the two SRE binding sites located in the 
first intron of the gene, are functional SREBP-1 binding motifs. Mutation of both 
SRE sites resulted in a significant decrease in luciferase expression. These two 
sites are conserved in mouse and human. Altogether, these data suggest that 
SREBP-1 directly regulates S6K. Future studies should include ChIP assays to 
confirm that SREBP-1 associates with the SRE binding sites in the S6K1 gene, 
as well as perform experiments in the HepG2 cell line to confirm that these 
conserved sites are also functional in humans. 
S6K has also been shown to phosphorylate multiple serine residues on 
IRS1 [199]. Phosphorylation of IRS1 on these residues inhibits its interaction with 
the insulin receptor, leading to decreased phosphorylation of tyrosine’s and 
reduced downstream signaling [200]. Our data showed that the SREBP-1 
depleted db/db mice had lower levels of IRS1Y612, suggesting other factors 
impede insulin signaling separate from S6K1 levels. 
The mTOR pathway and the insulin signaling pathway are interconnected 
to decide the cellular fate (survival, growth, proliferation, apoptosis), based on 
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nutrient availability [101]. Our results have shown that knocking down SREBP-1, 
a key transcription factor during conditions of nutrient abundance, affects the 
mTOR and insulin signaling pathways. Db/db mice treated with shSREBP-1 
adenovirus showed increased levels of basal AktSer473, compared to the control 
group, shSCR. The absence of SREBP-1 and the subsequent drop in glycolysis 
and ATP synthesis during fed conditions, may have been sensed as a drop in 
energy availability, thus inhibiting mTORC1 and activating mTORC2, resulting in 
increased AktSer473. S6K is one of the multiple molecules that phosphorylate 
Rictor, a subunit of the mTORC2 complex [201]. Phosphorylation at the Thr1135 
residue leads to weakened activity of mTORC2. Given that mTORC2 is 
responsible for phosphorylating Akt at Ser473, it is conceivable that reduced 
S6K1 would lead to lack of Rictor phosphorylation, thereby increasing mTORC2 
activity and AktSer473 phosphorylation. Our data showed that silencing SREBP-1 
in db/db mice increased Rictor protein levels, and decreased phosphorylation of 
RictorThr1135. This may provide a mechanism by which lower S6K1 may have 
caused upregulation in AktSer473 phosphorylation. Thus, by regulating S6K1, 
SREBP-1 may indirectly control the insulin signaling pathway (Fig. 26). Our 
model predicts that silencing SREBP-1 leads to decreased insulin signaling, and 
hence, lower AktSer473 phosphorylation. However in a hyperinsulinemic state, the 
depletion of SREBP-1 results in improper upregulation of AktSer473, due to the 
lack of mTORC2 inhibition.  
The glycolysis/lipogenesis pathway is enhanced and contributes 26% of 
triglycerides in liver of NAFLD patients, relative to only 5% in normal individuals 
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[36]. In ob/ob and db/db mice, it is also enhanced approximately 10-fold [39]. 
Thus, reducing this pathway in db/db mice activated AMPK, which in turn, 
inhibited mTORC1, and increased mTORC2 activity. Thus, the increase in 
AktSer473 is most likely not due to increased insulin signaling, but an inappropriate 
response to the inhibition of insulin action. Moreover, this would suggest that a 
certain amount of SREBP-1 may be needed in insulin resistant states, and 
complete knock down of SREBP-1 is only beneficial in reducing hepatic 
steatosis.  
Studies have shown that SREBP-1 is needed for cancer cell survival. This 
is due to the need for lipid and protein homeostasis to sustain growth [110]. 
Decreasing SREBP-1 led to stress and cell death, as well as ROS production 
and inhibition of protein synthesis [110]. More specifically, human hepatocellular 
carcinoma has been shown to be associated with increased lipogenic gene 
expression as well as increased Akt levels, correlating with a worst prognosis 
[115]. Thus, SREBP-1 depletion would be a valuable therapeutic tool in treating 
HCC and other cancers.  
Overall, this work highlights the notion that SREBP-1 regulates other 
pathways besides its known role in fatty acid synthesis (Fig. 27). The data 
generated from this thesis has provided evidence that SREBP-1 regulates 
carbohydrate metabolism, and most likely protein synthesis, by activating S6K1. 
Moreover, we show that SREBP-1 is needed for proper insulin signaling. Thus, 
its depletion does not result in improved glucose control in obese db/db animals. 
Nevertheless, it is possible that partial depletion has therapeutic value, and 
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results in lower lipid accumulation while preventing the negative effects on 
carbohydrate metabolism associated with its complete depletion. Our data also 
provide a mechanism by which reducing SREBP-1 in cancer cell lines reduces 
cell viability, as these cells require protein production for sustained growth and 
proliferation. Hence, SREBP-1 could be an appropriate target for treatment of a 
variety of tumors. 
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Figure 26.  Effects of silencing SREBP-1 on the insulin and mTOR 
pathways. Under basal conditions, silencing SREBP-1 leads to a decrease in 
insulin signaling and AktSer473. Under chronic insulin conditions, the lack of 
SREBP-1 decreases glycolysis and lipogenesis, activating AMPK, which 
negatively regulates mTORC1. The drop in S6K1 results in lack of mTORC2 
inhibition, increasing AktSer473 phosphorylation.  
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Figure 27.  Central role of SREBP-1. This work, as well as other studies, have 
highlighted the various roles SREBP-1 plays in regulating metabolic processes 
as well as cell proliferation/growth and cancer stability. 
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•  Experienced in maintaining human cell lines, and 
administering various drug treatments on cells 
•  Responsible for ordering laboratory reagents, making stock 
solutions, and instructing and supervising/mentoring new 
laboratory personnel 
           
2006-2007               Undergraduate Biology Research Assistant, NIH-IMSD 
                                Scholarship Viola Ellison Lab, Indiana University,        
                                Bloomington, IN 
 • Work primarily focused on sub-cloning and making GFP 
variant construct of human gene Ctf4. 
•  Performed western blotting, transformations, and gene  
amplification (PCR) 
 
 
 
Summer 2006          Undergraduate Researcher,  
             Louis-Stokes Alliance Minority Participant (LSAMP)  
                                 Scholarship Viola Ellison Lab, Indiana University,  
                                 Bloomington, IN 
•  Work primarily focused on sub-cloning, PCR amplification, 
                                 immunoblotting, transformations, DNA transfections via    
                                 lipofectamine into Hela cells 
 
Summer 2005          Undergraduate Researcher, NIH-IMSD Scholarship 
                                 Viola Ellison Lab, Indiana University, Bloomington, IN 
•  Work primarily focused on sub-cloning and PCR 
•  Performed in vitro transcription/translation assay 
•  Performed protein  induction for gene expression of  A1U 
and purification of A1U 
 
2005-2007               Secretary for University Coalitions for Global Health 
 
2003-2007               Biology Club Member 
 
2008                        Middle Way House Volunteer 
 
 
PUBLICATIONS 
 
1. Jideonwo, V., Ruiz, R., Surendran, S., Ahn, M., Morral, N. SREBP-1 
regulates the mTOR pathway through transcriptional activation of S6K. In 
preparation. 
 
2. Surendran ,S., Jideonwo, V., Merchun, C., Ahn, M., Murray, J., Ryan, J., 
Dunn, K., Kota, J., Morral, N. Gene targets of mouse miR-709: regulation a 
distinct pools. Scientific Reports 6: 1-10 (2016) 
 
3. Ruiz, R*., Jideonwo, V*., Ahn, M., Surendran, S., Tagliabracci, VS., Hou, Y., 
Gamble, A., Kerner, J., Irimia-Dominguez, JM., Puchowicz, MA., DePaoli-
Roach, A., Hoppel, C., Roach, P., Morral, N. Sterol Regulatory Element 
Binding Protein-1 (SREBP-1) is required to regulate glycogen synthesis and 
gluconeogenic gene expression in mouse liver. Journal of Biological 
Chemistry 289:5510-5517 (2014). *Equally contributed. 
 
 4. Drury DW, Ehmke RC, Jideonwo VN, Wade MJ. Developmental trajectories 
and breakdown in F1 interpopulation hybrids of Tribolium castaneum. Ecology 
and evolution 3(7):1992-2001 (2013). 
 
5. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, 
Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, 
Goodwin CB, Hui SL, Peacock M, White KE. Iron deficiency drives an 
autosomal dominant hypophosphatemic rickets (ADHR) phenotype in 
fibroblast growth factor-23 (FGf23) knock-in mice. Proceedings of the 
National Academy of Sciences of the USA 108(46):E1146-1155 (2011). 
 
6. Drury DW, Jideonwo VN, Ehmke RC, Wade MJ.. An unusual barrier to gene 
flow: perpetually immature larvae from inter-population crosses in the flour 
beetle, Tribolium castaneum. Journal of evolutionary biology 24 (12):2678-
2686 (2011). 
 
 
PRESENTATIONS 
1.  Victoria Jideonwo, Miwon Ahn, Sneha Surendran, Rafaela Ruiz, Yonyyong 
Hou, Núria Morral. Role of SREBP-1 as Regulator of S6k1 in the Liver. 
American Diabetes Association’s 76th Scientific Sessions, New Orleans, LA, 
June 10-14, 2016 
 
2.   Victoria Jideonwo, Miwon Ahn, Sneha Surendran, Rafaela Ruiz, Yongyong 
Hou, Núria Morral. Regulation of insulin signaling and S6K by the 
transcription factor SREBP-1. 1st Annual Center for Diabetes and Metabolic 
Diseases Symposium, Indiana University School of Medicine Indianapolis, IN, 
August 7, 2015   
 
3.  Victoria Jideonwo, Yongyong Hou, Sneha Surendran, Aisha Gamble, Núria 
Morral. Investigation for the role of CPT1A over-expression for treatment of 
non-alcoholic fatty liver disease.  5th Annual Midwest Graduate Research 
Symposium (MGRS), University of Toledo, Toledo, OH, March 29, 2014 
 
4.  Victoria Jideonwo. A role for Carnitine Palmitoyltransferase 1A (CPT1A) 
overexpression in treatment of non-alcoholic fatty liver disease. Department 
of Medical and Molecular Genetics Research Club, Indiana University School 
of Medicine, Indianapolis, IN, March 25, 2014   
 
5.   Victoria Jideonwo and Viola Ellison.  Analysis of Subcellular Localization 
and Colocalization of Sister Chromatid Cohesion Establishment Factor Ctf4.  
Poster presented at LSAMP Indiana and Midwest Crossroads AGEP Second 
Annual Joint Conference, West Lafayette, IN November 2006. 
